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Preface 
It is sad that in their lifetime, patients with type 2 diabetes suffer from quality of life reducing 
microvascular complications as retinopathy that may lead to blindness, nephropathy with the risk of renal 
failure and dialysis, and neuropathy with intangible pain and amputations. However, ultimately, the 
majority of the patients with type 2 diabetes will die of premature macrovascular disease prior to a 
disabling cerebrovascular catastrophe or congestive heart failure following a silent myocardial infarction. 
Because of the malignant nature of type 2 diabetes and a long symptom-less period prior to the 
diagnosis, the patients often experience belated admissions and greater cardiac morbidity and mortality. 
And even if there have been major advances and successes in the understanding and treatment of 
cardiovascular disease during the last decades, patients with type 2 diabetes with multiple cardiovascular 
disease risk have not yet obtained the full benefits of these endeavours. Both micro- and macrovascular 
complications to type 2 diabetes are potentially preventable given prompt diagnosis and effective patient 
and professional education as well as comprehensive care.  
 
 This PhD study was initiated at the suggestion and guidance of chief physician Jørgen 
Fischer Hansen MDSc, when I worked as a resident at the department of Cardiology at Bispebjerg 
University Hospital. Elaborating the DANSUK protocol, fundraising, developing the educational diabetes 
programme while undertaking the intensified patient care in the unit of cardiac rehabilitation was a great 
educational and personal challenge which at times seemed overwhelming. 
 
This dissertation will describe type 2 diabetes from a cardiovascular perspective. Studies in 
preventing the development of type 2 diabetes in patients with impaired glucose tolerance, prevalence of 
impaired glucose metabolism among patients with ischemic heart disease and the body of evidence in 
secondary preventive treatment of type 2 diabetes are scrutinized. Methods and results of the DANSUK 
study are described in details and the implications of type 2 diabetes and prediabetes in the settings of 
comprehensive cardiac rehabilitation are discussed. 
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List of abbreviations and acronyms: 
 
ADA      American Diabetes Association 
ABPI      Ankle-brachial pressure index 
ACEI      Angiotensin-converting enzyme inhibitor 
ARA      Angiotensin receptor-II antagonist 
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BMI      Body mass index 
CVD      Cardiovascular disease 
CHF      Congestive heart failure 
CR      Cardiac rehabilitation 
DANSUK      Det DANske stadium af hjertepatienter med SUKkersyge 
FPG      Fasting plasma glucose 
GIK      Glucose-insulin-potassium-infusion 
HbA1c      Glycosylated haemoglobin A1c 
HDL      High density lipoprotein 
HOMA-IR      Insulin resistance based on the homeostasis model 
HR      Patients at high-risk for ischemic heart disease 
IHD      Ischemic heart disease 
IFG      Impaired fasting glucose 
IGM      Impaired glucose metabolism synonymous with glucose intolerance 
IGT      Impaired glucose tolerance 
KT2DM      Known T2DM at baseline 
LDL      Low density lipoprotein 
Mets      1 Mets denotes resting metabolic rate at 3.5 ml O2/kg/min 
MI      Myocardial infarction 
NGT      Normal glucose tolerance 
ST2DM      Screen-detected T2DM 
OGTT      Oral glucose tolerance test 
PAD      Peripheral artery disease 
Prediabetes      Designates IGT and IFG 
T1DM      Type 1 diabetes mellitus 
T2DM      Type 2 diabetes mellitus 
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UKPDS      UK Prospective Diabetes Study  
VLDL      Very low-density lipoprotein 
WHO      World Health Organization 
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Part I: Type 2 diabetes mellitus – a cardiovascular perspective 
 
1. Introduction and objectives 
 
Type 2 diabetes (T2DM) is a complex clinical problem that has reached epidemic proportions. The World 
Health Organisation (WHO) has proclaimed that in the year of 2025 at least 300 million people (5.4% of 
the worlds population) will suffer from T2DM and as today the disease accounts for 4 million deaths per 
year that is close to 9% of global deaths [1-3]. Globalization and the increasing prevalence of obesity and 
sedentary lifestyle are key contributors to the raising prevalence of T2DM and prediabetes throughout the 
world [4-8]. The overall prevalence of cardiovascular disease (CVD) is as high as 55% among patients 
with newly diagnosed T2DM causing up to 80% of deaths among these patients [9-12]. The cardiovas-
cular mortality rate is doubled in men who have T2DM compared to their normal metabolic counterparts 
and more than quadrupled in women in whom T2DM tends to eliminate the usual female advantage in 
risk of death from CVD [13-16]. Type 2 diabetes is also a recognized risk factor for poor outcome after 
myocardial infarction (MI) and after either percutaneous or surgical coronary revascularization [17-20], 
making secondary prevention in these patients highly demanding. Since mortality after MI are de-
creasing, the potential need for cardiac rehabilitation (CR) in the population of MI survivors, is growing 
[21]. Moreover, as duration of hospital stays for MI have decreased over time, reducing the opportunity 
for in-hospital based risk factor intervention, outpatient hospital-based CR has become an important 
instrument in obtaining and continuing lifestyle improvements [22].  
Cardiac rehabilitation has been defined by the WHO as ‘the sum of activity required to 
influence favourably the underlying cause of the disease, as well as to ensure the patients the best 
possible physical, mental and social conditions so that they may, by their own efforts, preserve, or 
resume when lost, as normal a place as possible in the life of the community’ [23]. In 1994 the American 
Heart Association declared that CR should not be limited to an exercise training programme but should 
also include an individualized comprehensive, multifactorial intervention encompassing modalities as 
baseline patient assessment, patient education, dietary counselling, smoking cessations, psychosocial and 
vocational support, risk factor control including appropriate use of cardioprotective drugs and clinical 
follow-up visits [24]. 
The prevalence of T2DM in patients with ischemic heart disease (IHD) attending CR has 
been estimated to 20-30% [25-28]. Although studies have reported beneficial impact of CR on outcome 
in these patients, most data are generated from small trials before the era of reperfusion and revascula-
rization and includes mostly middle-aged men [29,30]. Recently a meta-analysis has indicated that a 
broader target group could benefit from comprehensive CR [31]. T2DM causes lesser participation in CR 
programmes and independently predicts re-hospitalizations [32,33] indicating that patients with T2DM 
and CVD are more ill and disabled than their metabolic normal counterparts. Patients with T2DM seem to 
highly benefit from treatment reducing morbidity of CVD, but they have often been withheld from 
evidence-based treatment [34-37]. Patients with T2DM also do not appear to obtain the same benefit 
from standard CR programmes as patients without T2DM [35]. A survey in 2002 among randomly 
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selected patients with T2DM revealed that 70% of the patients did not believe they were at serious risk 
for CVD [38]. This ignorance among the patients and inadequacy among the care providers underline the 
great educational needs and future challenges in the prevention and treatment of CVD in patients with 
T2DM. 
  
The objectives of this dissertation are: 
1. To estimate the prevalence and characteristics of known and unrecognized type 2 diabetes, 
impaired glucose tolerance, and impaired fasting glucose in accordance with modern diagnostic 
criteria in a group of patients referred to hospital-based outpatient comprehensive cardiac 
rehabilitation – The DANSUK study. 
2. To examine, in the DANSUK population, the concordance rate between impaired fasting glucose 
and impaired glucose tolerance and thereby evaluate a systematic use of an oral glucose tole-
rance test. 
3. To describe, in the DANSUK population, independent predictors of different stages of impaired 
glucose metabolism and clarify differences in cardiovascular risk profile between these groups. 
4. To develop and implement a chronic disease management programme including optimal diabetes 
and cardiac risk factor control in patients with type 2 diabetes or impaired glucose tolerance. 
5. To evaluate the effect of intensified comprehensive cardiac rehabilitation in patients with type 2 
diabetes or impaired glucose tolerance compared to usual care. 
 
1.1. Source reference 
In the following chapter secondary diabetes prevention trials, observational trials as well as mono- and 
multifactorial controlled risk reducing trials in patients with T2DM with and without CVD will be presented. 
Individuals with T2DM or impaired glucose tolerance (IGT) were either the focus of the mentioned 
studies or subgroups of larger trials. It is beyond the frames of this dissertation to give a thorough 
description of all the non-pharmacological core components of CR. The review will mainly cover the latest 
evidence of pharmacological intervention towards patients with T2DM and CVD addressing hyper-
glycaemia, systemic hypertension, and lipid control on which the physician performed intensified treat-
ment in the DANSUK study was based. The searches were all done in Medline/PubMed in the autumn of 
2005 focusing on randomized controlled trials, systematic reviews and meta-analyses, published in 
English after the period of 1990, involving only adults with T2DM or IGT. Keywords were ‘type 2 dia-
betes’, ‘diabetes’ and ‘randomized controlled trials’, ‘cardiac rehabilitation’ combined with: 
 
Secondary diabetes prevention studies: ‘impaired glucose tolerance’, ‘diabetes prevention’, ‘lifestyle 
intervention’, ‘behavioral modification’. 
Glucose lowering trials: ‘hyperglycaemia’, ‘glucose control’, ‘haemoglobin A1c’, and names for different 
individuals drugs 
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Blood pressure lowering trials: ‘systemic hypertension’, ‘arterial hypertension’, ‘hypertension’, and names 
for different individual drugs. 
Lipid lowering trials: ‘dyslipidaemia’, ‘lipid control’, ‘hypercholesterolemia’, ‘statin’ and names for different 
individual drugs 
 
2. Background 
2.1. Prevalence of IGM in patients with IHD 
Impaired glucose metabolism (IGM) is common in patients with IHD, but a major obstacle in treating and 
preventing T2DM and the associated CVD is that it often remains undiagnosed. The importance of early 
diagnostic procedures of T2DM is seen in many studies [39-42], where the prevalence and severity of 
CVD are closely related to the duration of T2DM.  
It has been known for years that non-diabetic patients with an acute myocardial infarction 
(MI) often present with glucosuria and hyperglycaemia [43,44]. The stress-induced increased glucose 
turnover and insulin resistance of hyperglycaemia have previously been interpreted as a plea for 
tolerating moderately elevated blood glucose levels during MI although hyperglycaemia in these patients 
was associated with a worse prognosis compared to normoglycaemia. Table 2.1 shows some of the 
recent studies establishing the prevalence of IGM in groups of patients mainly with IHD. Through the last 
decades the prevalence of T2DM, IGT and IFG in patients with MI have increased probably due to the 
global increase in obesity and improved diagnostic procedures [57]. The prevalence of known T2DM in 
patients with MI lies between 15%-24% [34,58,59] and the prevalence of previously unrecognized T2DM 
seems to be in the same range or even much higher as shown in a prospective study of Glucose 
tolerance in patients with Acute Myocardial Infarction (GAMI) which included only patients with no 
previous diagnosis of T2DM and a FPG-level above 11.1 mmol/l [47]. In the same study, IGT was 
diagnosed in 40% of the patients before discharge and it was suggested that FPG taken on admittance 
day 4 and an oral glucose tolerance test (OGTT) before discharge could be used as early markers for IGM 
[47]. The European Heart Survey revealed that more than 60% of the patients admitted with MI had 
IGM, thus IGM is more common among ischemic patients than normal glucose tolerance (NGT) [27]. A 
prevalence of IGM as high as 85% has also been reported in individuals referred to elective coronary 
angiography [54,52] and the advancement of coronary artery disease seems to correlate with the degree 
of glucose deterioration [52]. The prevalence of the specified classes of glucometabolic abnormalities in 
patients eligible for CR has never been investigated. 
Like the increase of IGM in patients with CVD, the prevalence of IGM has also increased in 
the Danish background population. Coincide with an increase in BMI over a 22-year period, a marked 
increase in the prevalence of T2DM and IGT among 60-year-old individuals has been observed [60]. In 
the DANSUK study there is no matched group of non-cardiac diseased individuals. As part of a popula-
tion-based primary prevention study on CVD and T2DM, the Inter99 study will therefore be referred to as 
an external reference population to the DANSUK study, representing the general population in Denmark 
(overall N=13.016). The Inter99 study determined the age- and sex-specific prevalence of IFG, IGT,  
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Table 2.1. Recent studies investigating the prevalence of glucose intolerance in patients with high-risk of ischemic heart disease 
(IHD) and in patients with established cardiovascular disease (CVD)  
             
  Publication Patient Number of Age Male BMI KT2DM ST2DM  IGT  Isolated  NGT    
  year category patients (mean) (%) (mean) (%) (%) (%) IFG (%) (%)   
Surveys                         
MMWR45
*
 2003 CVD 720 62 41 NA
**
 25 NA NA NA NA   
European heart survey27 2004                       
          Acute group   CVD 2107 67 70 27 31 15 22 3 29   
          Elective group   CVD 2854 68 71 28 30 10 22 3 35   
EUROASPIRE I & II28 2004 CVD 5556 63 75 29 20 9 NA NA NA   
Ischemic heart disease                         
Farrer et al.46 1995 elective CABG 353 59 69 26 6 4 19 NA 72   
The GAMI study47 2002 MI 181 64 68 27 NA 25 40 NA 35   
Conaway et al.48 2005 MI 1199       27 11 NA 29 33   
High-risk of IHD                         
Fujiwara et al.49 1995 elective CAG 127 59 100 23 NA 35 32 NA 33   
Seibaek et al.50 1997 elective CAG 99 59 100 26 NA 16 21 NA 63   
Natali et al.51 2000 elective CAG 2253 60 73 27 10 2 NA NA 88   
Kowalska el al.52 2001 elective CAG 363 53 100 28 NA 16 36 NA 48   
The LURIC study53 2003 elective CAG 3266 64 70 28 17 15 NA NA 68   
Wascher et al.54 2004 elective CAG 160 65 66 28 23 32 30 NA 15   
Cardiac rehabilitation                         
Milani et al.26 1996 Mainly IHD 291 64 73 29 24 NA NA NA 76   
Suresh et al.35 2001 IHD 1804 58 77 NA
***
 12 NA NA NA 88   
Banzer et al.55 2003 Mainly IHD 952 62 54 34 26 NA NA NA 74  
The ELMI study25 2003 Mainly IHD 305 64 83 28 20 NA NA NA 80  
Hindman et al.56 2005 Mainly IHD 1505 63 73 32 19 NA NA NA 81  
CVD, cardiovascular disease; MI, myocardial infarction; IHD, ischemic heart disease; CAG, coronary angiography; BMI, body mass index;   
KT2DM, known type 2 diabetes; ST2DM, screen detected type 2 diabetes; IGT, impaired glucose tolerance; IFG, impaired fasting glucose; NGT,  
normal glucose tolerance; NA, data not available; MMWR, Morbidity and Mortality Weekly Report       
* information based on telephone interview           
** 75% of the patients were overweight (BMI>25 kg/m2 and BMI<30 kg/m2) and 30% were obese (BMI>29.9 kg/m2)      
*** 38% of the patients were overweight having a BMI >29.9 kg/m2          
 
screen-detected type 2 diabetes (ST2DM) and known type 2 diabetes (KT2DM) in a Danish population 
aged 30-60 years (N=6.784) [61]. The prevalence of IGM increased with age and the crude prevalence of 
IFG was 8.1% (age group of 60 years; women: 5.1% and men: 16.3%). The crude prevalence of IGT 
was 11.7% (age group of 60 years; women: 17.3%; men: 17.8%). The total prevalence of T2DM in the 
age group of 60 years was 12.2% for women and 15.5% for men (ST2DM for women: 6.3% and men: 
9.7%) [61]. Likewise parallels will be drawn between the DANSUK study and the population-based pan-
European Diabetes Epidemiology Collaborative analysis Of Diagnostic criteria in European studies 
(DECODE) (N=47.396), that included individuals aged 60-79 years and with no previously knowledge of 
T2DM [62]. 
 
2.2. Secondary prevention of T2DM 
Impaired glucose tolerance implies an increased risk for T2DM and CVD, which is often present prior to 
the diagnosis of T2DM [63-65]. The annual progression rate of IGT to T2DM ranges from 4-8% in 
different populations [66,67]. The progression of IGT to T2DM may be prevented or postponed by 
behavioural modifications as weight loss and regular exercise [68-70]. Physical exercise improves blood 
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lipid profile, reduces blood glucose, and is associated with substantial reductions in CVD risk and mortality 
[71-74]. Thus physical exercise is one of the core elements in rehabilitation of patients with IHD with or 
without T2DM. Several randomized controlled trials have shown the beneficial effects of lifestyle inter-
vention programmes in high-risk populations [68-70,75-77]. Table 2.2 shows some of the first larger well-
controlled diabetes prevention trials with a transparent randomization and well-defined study groups. The 
applied lifestyle intervention programmes in these studies are comparable to the ones recommended in 
CR settings by the American Heart Association [24] and the European Society of Cardiology [78]. 
Although initial successful, many of the non-pharmacological diabetes preventive treat-
ment intervention programs have difficulties in producing long-term changes in behaviour, weight, or 
physiological parameters. Even if the progression rate was lower than in the control groups, the 
intensively treated groups continued to develop T2DM at rates greater than their metabolic normal 
counterparts throughout the trials. To obtain a real prevention of developing T2DM on a long-term basis, 
additional pharmacotherapy with metformin, arcobase, and most likely the thiazolidinediones may be 
essential [75-77]. A cost-benefit analysis of the Diabetes Prevention Program [69] found that, despite the 
greater efficacy of lifestyle intervention, the cost per case of T2DM prevented was higher than that of 
metformin [79]. But it is important to notice that metformin was almost ineffective in individuals above 
the age of 60 years and in patients with a BMI less than 30 kg/m2 [69]. 
 
Table 2.2. Randomized controlled diabetes prevention trials in patients with IGT 
   
  Pub. Type of Study Number of Mean Mean Intervention form RRR% in  
  year IGM period patients age BMI   development of T2DM*  
Da Qing Study
68
 1997 IGT 6 577 45 26 Diet 31%  
             Exercise 46%  
             Diet+exercise  42%  
              Control    
The Finnish Diabetes 2001 IGT 3.2 522 55 31 Intensified programme 58%  
 Prevention Study70             Conventionel guidelines + exercise    
Diabetes Prevention 2002 IGT 2.8 3234 51 34 Intensified programme 58%  
Programme69            Metformin 31%  
              Placebo    
TRIPOD75 2002 GDM 2.5 235 35 30 Troglitazon 56%  
              Placebo    
STOP-NIDDM76 2002 IGT 3.3 1449 54 31 Arcobase 25%  
              Placebo    
XENDOS77 2004 21% IGT 4 3304 43 37 Zenecal+ lifestyle councelling 37%  
    79% NGT         Placebo + lifestyle councelling    
IGM; impaired glucose metabolism; IGT, impaired glucose tolerance; GDM, gestational diabetes mellitus; RRR, relative risk reduction  
* all p<0.05   
 
Other cardiovascular medications have been mentioned as being able to delay or prevent diabetes 
properly by improving insulin sensitivity or by mechanisms that are not yet known [80-83]. Several trials 
have compared the possible diabetes preventive effect of angiotensin-converting enzyme inhibitors 
(ACEI) with drugs known to worsen glucose tolerance. It may also be noted that the diagnosis of T2DM 
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in many of these trials was based on either self-reported T2DM or on fasting plasma glucose (FPG) values 
equal to or above 7.0 mmol/L [81,82]. 
In 1997 the American Diabetes Association (ADA) followed by the WHO introduced the 
concept of IFG, defined as FPG values between 6,1-6,9 mmol/l (measured on two occasions), in order to 
limit the need for the more time consuming OGTT [84,85]. The definition of IGT is based on an OGTT. 
Since 1997 evidence emerged that individuals diagnosed on behalf of an OGTT had a different 
cardiovascular and diabetic risk profile than individuals diagnosed on FPG-values alone. In an attempt to 
obtain a higher concordance between IFG and IGT, the ADA recently recommended a further lowering of 
the glucose values defining IFG to concentrations between 5,6-6,9 mmol/L [86]. It is worthy of note that 
the DECODE study [87] and other studies [88,89] showed that IGT was a stronger predictor of mortality 
than elevated FPG. The association between IFG and CVD seems less clear [89]. That IGT is a stronger 
predictor of CVD mortality than IFG could be explained by the higher progression rate to T2DM [90]. The 
difference between IGT and IFG with regard to CVD risk may be of great clinical importance. Using the 
ADA criteria to screen for T2DM will misclassify some of the patients with isolated IGT and will not 
discriminate those with isolated IFG from those with both IGT and IFG, who are at higher risk for CVD. 
Early T2DM may also manifest itself as postprandial hyperglycaemia while FPG measurements and HbA1c 
levels may be normal. 
Arguments for the recent lowering of the FPG level for IFG could be explained by data 
from observational studies suggesting that hyperglycaemia is an independent risk factor for CVD with no 
obviously apparent threshold [91-94]. The possible relationship between the degree of hyperglycaemia 
and CVD is based on large observational studies and two meta-analyses [39,95,96]. It is estimated that 
1% rise in HbA1c values above 5% increases the risk for CVD by about 20% [39]. In another 
observational study of 4662 men without T2DM, individuals with HbA1c of 5.0% to 5.5% had a 2.5-fold 
increased risk of dying from CVD, compared to individuals having HbA1c levels below 5.0% [97]. 
In conclusion, it is important to emphasize from the mentioned randomized controlled 
trials, that the aim was diabetes prevention. There is still no solid evidence from prospective randomized 
controlled trials that prevention of T2DM in patients with IGT reduces morbidity or mortality of CVD. 
Before implementation of preventive strategies towards patients with isolated IFG e.g. in the settings of 
CR, a better understanding of the prognostic significance of isolated IFG is needed, as it is not yet 
obvious, that the benefit of preventive measures tested in patients with IGT will apply to patients with 
isolated IFG. 
 
2.3.  Mono- and multifactorial treatment of T2DM in reducing risk of CVD 
When treating T2DM it is crucial to limit the number of cardiovascular risk factors because the mortality 
rate from CVD doubles in patients with T2DM with one additional risk factor and more than triples with 
three additional risk factors [10,98]. The observation that patients with T2DM without CVD had as high a 
risk of future CVD events as patients with CVD without T2DM has changed the whole concept of 
prevention in patients with T2DM [99]. The disease is now acknowledged as a CVD risk equivalent. Once 
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T2DM has been diagnosed, the approach to CVD is that of secondary prevention [100] even though this 
alignment of T2DM with CVD has been both consolidated [101] and disputed [102]. 
For many years treatment of T2DM has been empirical based on extrapolations of inter-
vention forms for type 1 diabetes (T1DM) and for patients with NGT. In the last decades several single 
drug intervention trials against risk factors such as hypertension and dyslipidemia have emerged often 
with a more pronounced benefit in the patients with T2DM revealed by sub group analyses. Seven 
randomized multifactorial intervention trials towards patients with T2DM are identified [103-111]. In most 
of these trials, the patients had newly diagnosed T2DM and no established diagnose of CVD at inclusion. 
The STENO 2 study deserves some special attention [103]. The study randomized 160 patients with 
T2DM and microalbuminuria to intensified multifactorial intervention (N=80) or usual care at their general 
practitioner (N=80). Mean age was 55 years and women constituted nearly 25%. Almost 25% of the 
patients included had known IHD. The primary endpoint was nephropathy. Secondary endpoints were the 
incidence or progression of diabetic retinopathy and neuropathy. Macrovascular events and deaths were 
tertiary endpoints. At baseline the mean HbA1c was 8.5% and mean blood pressure was 148/86 mmHg 
and 20% of the patients were treated with ACEI and 13% with ASA. The main result of the STENO 2 
study was a reduction in risk of cardiovascular and microvascular events by 50% after a mean study 
period of 7.8 years. Up to 66% of the patients in the conventional group had received treatment at an 
outpatient diabetic clinic during study period [105]. 
 
2.4. Behavioural modifications 
Many of the risk factors for T2DM and CVD are modifiable through lifestyle changes that therefore are the 
basis in comprehensive CR programmes. Data from the UK Prospective Diabetes Study (the UKPDS) 
based on relatively young individuals with newly diagnosed T2DM found, that once T2DM has developed, 
hypertension, increased LDL-cholesterol, decreased HDL-cholesterol, and hyperglycaemia were greater 
risk factors for CVD than the precipitating factors for T2DM i.e. upper body obesity, decreased physical 
activity and hyperinsulinemia [112]. The first line of intervention aiming to reduce the cardiovascular risk 
is dietary therapy [113-115] along with smoking cessation and physical exercise [116]. Table 2.3 
emphasizes that the body of evidence for reducing both mortality and morbidity is well documented for 
the non-pharmacological treatment modalities and that they posses the same level of recommendation as 
the pharmacological treatment [117]. 
 Nutritional counselling lowers blood glucose [118,107], improves lipid profile [119,120] 
and blood pressure control [121], but because of the progressive nature of the T2DM, hyperglycaemia 
will arise and strict nutritional counselling alone has never been able to reduce LDL cholesterol by more 
than 0.65 mmol/l [120]. The possible effect on both the systolic and diastolic blood pressure is closely 
related to weight loss and sodium restricted diet but has never been investigated as a randomized 
controlled trial in patients with T2DM. 
Smoking cessation is of great importance in patients with T2DM and CVD as the rate of 
atherosclerotic progression in current smokers with T2DM is almost twice that seen in current smokers 
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without T2DM [122]. In patients with and without T2DM, a strong association exists between smoking 
and the risk of CVD [123]. Recent studies also including patients with T2DM, have reveiled that the 
longer duration of smoking and heavy smokers are at a higher risk of CVD [124,125]. Intensive 
counselling during admission with one-month follow-up seems more effective [126] than courses with no 
long-term follow-up [127]. 
Regular exercise improves insulin sensitivity and also improves plasma lipid levels, blood 
pressure, and body weight [128-130] but individuals with T2DM generally exhibit poor cardiovascular 
response, and may have to expend more effort for a given amount of work than their metabolic normal 
counterparts [131]. Among patients with known CVD, regular exercise has been shown to reduce the 
rates of CVD and all-cause mortality [132]. Physical exercise programmes for patients with T2DM are well 
described in CR settings in the US [133] and exercise is readily accessible and cost-effective in reducing 
CVD risks and should be encouraged in all patients. 
 
Table 2.3. Documented effect of some non-pharmacological and pharma-  
cological treatment modalities encompassed in comprehensive CR  [117]  
    
    Disease  
  Mortality progression   
Non-pharmacological treatment       
Exercise xxx xxx   
Smoking cessession xxx xxx   
Dietary guidance xxx xxx   
Pharmacological treatment       
Aspirin xxx xxx   
Statin xxx xxx   
Beta-blockers xxx xxx   
ACEI/ARA xxx xxx   
xxx, substantial benefits; xx, moderate benefits; x, slight benefit; ACEI, angio-  
tensin-converting enzyme inhibitor; ARA, angiotensin receptor-II antagonist  
 
An estimated 60% to 90% of all T2DM is related to obesity [134]. A weight gain of 5 kg in men increases 
the risk of CVD by almost 30% and the estimated changes in lipids and blood pressure related to this 
weight gain increases the risk by approximately another 20% [135]. Thus obesity is the true vicious 
playmate in T2DM. Surprisingly patients with T2DM only loose half the weight compared to their 
metabolic normal counterparts when receiving the same weight management programme [136]. Weight 
loss also improves glycaemic control [137] and may even cause a remission of diabetes [138]. The 
UKPDS demonstrated that a mean weight loss of 10 kg was sufficient to obtain normal FPG-values 
throughout the first year of the study. The more glycaemic deteriorated the patients were, the more they 
had to loose in weight to normalize FPG-levels [139]. Unfortunately intensive glycaemic control to achieve 
normal HbA1c values may cause weight gain [104]. Many patients with T2DM do not adhere to the 
recommended guidelines for diet and exercise [140]. Managing chronic diseases as T2DM and CVD can 
be a substantial source of stress, and patients with T2DM are more likely to be depressed than are those 
in the general population [26,141,142]. This can lead to poor adherence to lifestyle modifications as well 
as to pharmacotherapy [143]. 
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2.5. Treatment of hyperglycaemia 
Hyperglycaemia as a cause of vascular disease has been investigated clinically by examining the benefits 
of tight glucose control. The randomized controlled trials examining this issue are divided into studies 
focusing on the immediate effect of glucose-insulin-potassium (GIK)-infusion in patients with MI with a 
relatively short follow-up period (months) and in studies focusing on the long-term effect (years) of 
intensive glycaemic control. The possible beneficial effect of GIK-infusion to protect the ischaemic 
myocardium has been known since the 1960s [144] supported by the glucose hypothesis primarily 
asserted by Opie [145]. Many small studies [146-154] were systematically reviewed [155] involving 1932 
patients mainly from the pre-thrombolytic period and concluded that especially high-dose GIK scheme in 
the first few hours of MI with a treatment duration from 6 hours to 14 days, may play an important role 
in in-hospital mortality which was reduced by 28% (95% CI: 14-83, p=0.004), with an estimate of 49 
lives saved per 1000 patients treated. One of the first randomized controlled trials of GIK-infusion of MI 
in the era of reperfusion was the Diabetes mellitus Insulin Glucose infusion in Acute Myocardial Infarction 
study (DIGAMI) [156] (table 2.4.). This study included 620 patients with T2DM or hyperglycaemia (FPG ≥ 
11.1 mmol/l) on admission and assigned them to either conventional therapy or adjunctive therapy with 
GIK-infusion followed by a multidose insulin regimen for at least 3 months. Patients treated with GIK-
infusion had a significantly lower 1-year mortality (18.6% versus 26.1%, p=0.03) and three years relative 
mortality was reduced 25%. The studies to follow showed conflicting results of the effect of GIK-infusion 
that may be due to different dosage of insulin, infusion rate and considerable population diversity [157-
161]. A recent meta-analysis [162] addressing the effect of GIK-infusion regimes pooled almost 5000 
patients from 16 trials conducted from 1965 to 2003 [146-154,156-159,163-165]. The analysis indicated 
an 18% relative risk reduction in mortality (p=0.03). But the analysis should be interpretated with caution 
mixing high- and low-dose GIK-regimes and ischemic patients with or without congestive heart failure, 
the latter being especially vulnerable to volume load [164,165]. Thus the current evidence for the use of 
GIK-infusion in MI is still not conclusive [166] but an ongoing trial, combining reperfusion therapy and 
high-dose GIK-infusion, will maybe answer some of the questions [167]. 
Several studies have shown that chronic glycaemic control (as reflected by HbA1c) may be 
more effective in avoiding microvascular complications compared to macrovascular complications. The 
reduction of microvascular complications by improved glycaemic control was clearly demonstrated in the 
UKPDS where fasting glucose levels of less than 7.1 mmol/l resulted in a 25% relative reduction in the 
risk of microvascular disease over 10 years (p=0.01) [168]. Similar results were obtained in the smaller 
Kumamoto study in a relatively lean less Western like population [169,170]. A pronounced benefit of 
strict glycaemic control in patients with T1DM was found in the Diabetes Control and Complication Trial 
study (DCCT) that showed a reduction in the incidence of retinopathy, microalbuminuria and neuropathy 
by 76%, 39% and 60%, respectively [171]. The importance of glycemic control in preventing 
macrovascular complications is less consolidated especially in patients with T2DM. A systematic review 
from 1999 concluded that there was a weak association between hyperglycaemia and mortality [172]. 
Half of the 27 studies included, showed a positive association between hyperglycaemia and CVD, but 
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randomized as well as not randomized trials were included, and the variable degree of adjustment of 
other confounders not to mention the diversity in the used measurements of HbA1c and FPG, may allow 
the homogeneity of the analysis to be disputed. A meta-analysis investigating blood glucose threshold for 
increased mortality in patients with MI concluded, that hyperglycaemia is associated with an increased 
risk of in-hospital mortality in patients with and without T2DM. A non-fasting blood glucose threshold for 
increased mortality of acute MI for patients without T2DM was reported as 6.1 mmol/l and the threshold 
for patients with KT2DM was 10 mmol/l [173]. An observational study of hyperglycaemia in 336 patients 
with acute MI revealed that mortality was higher in patients with KT2DM (40%) compared to patients 
with NGT defined as a non-fasting admission plasma glucose less than 5.6 mmol/l (16%, p<0.05) and 
that mortality rose progressively to 44% for blood glucose above 11.0 mmol/l [174]. Intensive glycaemic 
control in patients with T1DM resulted in a decreased progression of the intima-media thickness that is a 
marker for increased risk for cardiovascular events [175]. Follow-up data from the same study have 
recently shown that the risk of cardiovascular events was significantly reduced by 42% in the intensively 
treated group compared to usual care [176]. 
 
Table 2.4. Glucose-lowering randomized controlled trials in patients with T2DM  
                 
  Pub. Duration Number of Age
*
 Male BMI
*
 T2DM History of Intervention form HbA1c
*
  FPG
*
 ∆HbA1c
*
 ∆FPG
*
 RRR% in   
  year (years) patients  (%)  duration* CVD (%)   baseline baseline % mmol/l CV events   
VASCDM
179
 1997 2.3 153 61 100 31 8 38 Insulin/glipizide v insulin 9.8 11.8 -2.1 -5.57 NS   
                               
KUMAMOTO
169
 1995 8.0 110 49 49 20 8 0 Multiple insulin v conventional 9.1 8.9 -2.2 -2.22 NO   
                 insulin injections             
UKPDS
168
 1998 10.0 3867 53 61 28 0 0 Diet/SU/insulin (intensive care) vs  7.1 8.0 -0.9† -1.33 NS††/**   
                  Diet/SU/insulin (usual care)         (p=0.052)   
DIGAMI I
156
 1995 1.0 620 68 63 27 0 60 Insulin-glucose infusion + insulin sc. 8.1 14.2 -0.3 NA 29   
(20% T1DM)                vs usual care         (p=0.027)   
DIGAMI II
161
 2005 2.1 1253 68 67 28 8 50 1) GIK-infusion + insulin long-term 7.3 12.7 -0.5 -0.9 NS   
                2) GIK-infusion + standard glucose control            
                  3) Local practice glycaemic control             
NS, not statistical significant; NO, few events to obtain any difference; NA, not avaible, SU, sulphonylurea; GIK, glucose-insulin-potassium; Pub. year, year of publication;  
CV, cardiovascular. 
*
 Mean values; 
†
 after one year; 
††
 RRR = 12% (p=0.03) for 'any diabetes-related endpoint' encompassing fatal and non-fatal MI, heart failure and angina  
** 
RRR = 39% (p=0.01) for MI in 753 overweight patients treated with metformin [177].  
 
Looking at the existing randomized controlled trials conducted after 1980 addressing whether improved 
glycaemic control reduces CVD in patients with T2DM, the Kumamoto Study including 110 patients did 
not find that good glycaemic control retards the progression of macrovascular disease but obtained 
significant risk reductions for nephropathy, retinopathy and peripheral neuropathy [169]. The difference 
in HbA1c between the study groups was substantial (table 2.4) but the event rate of macrovascular 
complications was low and did not reach statistical significance [169,170]. The larger UKPDS tested 
whether intensive glycaemic control with either sulphonylurea or insulin influenced the risk of micro- or 
macrovascular complications compared with conventional treatment [168]. More than 4000 patients with 
newly diagnosed T2DM and no CVD at baseline were treated for 10 years. The incidence of MI was 
reduced 16% but this reduction was only marginally significant (p=0.052). The overweight patients in the 
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same study treated with metformin obtained a significantly reduced risk of MI (relative risk reduction: 
39%, p=0.01) [177]. 
Epidemiological analyses of the UKPDS study estimates that a 14% decrease in risk of fatal 
or nonfatal MI is associated with a 1% lower mean HbA1c value [91]. This is almost similar to the 
findings in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), where a 10% increase in 
risk of mortality from IHD in T2DM patients was seen in association with a 1% increase in HbA1c [178]. 
The Veteran Affairs Cooperative Study on glycaemic control and complications in NIDDM (VACSDM) 
included relatively obese patients with dysregulated insulin-dependent T2DM [179]. Despite an excellent 
separation in HbA1c between the study groups that was maintained throughout the study period of 
nearly 3 years, there was a trend toward a worsening of cardiovascular outcome in the intensively 
treated patients (p=0.1). A possible explanation for this outcome was that a transient aggravation of 
other outcomes e.g. retinopathia had been observed in the intensive treatment of hyperglycaemia in 
patients with T1DM [180].  A new and larger trial addressing the same objective; the Veteran Affairs 
Diabetes Trial (VADT) began inclusion of the same kind of patients in 2000 [181]. The Diabetes mellitus 
Insulin Glucose infusion in Acute Myocardial Infarction II study (DIGAMI II) recruited 1253 patients 
suspected for acute MI. The patients were randomized into 3 treatment groups (table 2.4). A difference 
in cardiovascular mortality or morbidity between the 3 study groups was not observed. A possible 
explanations was a significant difference in baseline characteristics between the 3 groups due to different 
inclusion rates among the many centres and not following protocol procedures as prescribed, al-lowing a 
slackly procedure in the most intensively treated group (group 1) and cross-over treatment in the 
‘conventional’ treated group 3, where as many as 41% received extra insulin injections and 14% GIK-
infusion [161]. There are many limiting factors in the trials intervening against hyperglycaemia listed in 
table 2.4. Methods of assessment of blood glucose are heterogeneous and HbA1c assays vary and 
therefore make the comparability difficult [182]. 
In conclusion, the body of evidence of strict chronic glycaemic control is mostly based 
upon relatively young individuals (mean age: 58 years) with a relatively short duration of T2DM (range: 
0-8 years). The overall impact of glycaemic control on risk reduction and prevention of major 
cardiovascular events in patients with T2DM still remains controversial although metformin seems to be 
beneficial in obese patients. The cut-off value for the diagnosis of T2DM has been determined in the past 
by microvascular rather than macrovascular complications [183]. This diversity and the lack of 
unambiguous randomized controlled trials may explain why different advisory bodies recommend 
different HbA1c goal levels ranging from below 6.5% [78,184,185] to below 7.0% [186] to within the 
range of 7-8% [117]. Randomized controlled trials investigating risk-to-benefit ratios in older patients 
with a limited life expectancy and a long lasting T2DM are still lacking. Until now no randomized 
controlled trial have obtained and sustained a mean HbA1c level below 7% in the intensively treated arm 
throughout the study period. 
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2.6. Treatment of arterial hypertension 
The WHO has identified arterial hypertension as the single most important preventable cause of prema-
ture death [187]. The prevalence of arterial hypertension in patients with T2DM depends upon age, obe-
sity, diabetes duration, and the definition used. Using the criterion above or equal to 140/90 mmHg, up 
to 80% of the patients with T2DM have hypertension [188,189]. Using the recent recommendations of a 
treatment target below 130/80 mmHg, the prevalence of hypertension in T2DM patients is likely to be 
even higher [190-192]. About twice as many patients with T2DM are hypertensive compared to 
normoglycaemic patients [193]. In patients without overt T2DM, hypertension is often associated with 
insulin resistance, dyslipidemia, and increased risk of CVD [194]. In patients with T2DM or IGT, 
hypertension is found to be a particularly strong risk factor for CVD and death [195] and the increased 
risk are higher at every level of systolic pressures assessed and more pronounced if the patients also 
have nephropathy [10,196]. Table 2.5 summarises randomized controlled trials addressing the impact of 
different antihypertensive therapies on major cardiovascular outcome in patients with T2DM. Only the 
UKPDS [197], the Appropriate Blood pressure Control in Diabetes study (ABCD) [198] and the Fosinopril 
versus Amlodipine Cardiovascular Events Trial (FACET) [199] were designed to specifically examine 
patients with T2DM. The result of major cardiovascular events in the diabetic population in the remaining 
studies listed in table 2.5 are based on subgroup analyses of larger trials examining the effect of lowering 
the blood pressure compared to placebo [200,201], between different active agents [202-206] or in a 
strict versus less strict strategy using the same first-line active agent in both treatment groups [207,197]. 
Intensive treatment of arterial hypertension seems to be especially beneficial in patients 
with T2DM. In fact, in several of the larger trials, the sub group analyses of the diabetic population were 
the only cardiovascular outcome to reach statistical significance [201,202,207]. Despite the certainty of 
therapeutic benefit, some of the studies shown in table 2.5 have also caused controversies especially in 
the use of potentially harmful drugs [198,199]. The interpretation of the results of the ABCD study [198] 
and the FACET study [199] has caused some dispute. These two studies both had cardiovascular events 
as secondary outcome. They both compared the efficacy of a dihydropyridine calcium-channel blocker 
with an angiotensin-converting enzyme inhibitor (ACEI) and suggested that ACEIs were preferable 
compared to calcium-channel blockers and that the latter could possess a harmful effect in the treatment 
of hypertension in patients with T2DM. In contrast to the ABCD and the FACET studies, the Systolic 
Hypertension in Europe Trial (Syst-Eur) showed that treatment with a long-acting calcium channel blocker 
was both effective and beneficial in reducing cardiovascular morbidity and mortality [201]; a conclusion 
that was later reproduced in several other studies [209-212]. The UKPDS was both a study of the effect 
of tight blood pressure control on microvascular and macrovascular complications as well as a comparison 
of a beta-blocker versus an ACEI [197,209]. A target blood pressure below 150/85 mmHg resulted in a 
24% risk reduction in diabetes-related endpoints (p<0.005), including a 34% risk reduction (p<0.02) in 
combined macrovascular disease (MI, sudden death, stroke, and peripheral arterial disease (PAD)). The 
risk of heart failure decreased 56% (p<0.005) while the 21% reduction in MI did not reach statistical 
difference [197]. The study was also the first to show, in patients with T2DM, a beneficial effect of blood 
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pressure lowering therapy on microvascular complications that decreased 37% in the intensively treated 
group. There was no difference within the tight intervention group between patients treated with the 
beta-blocker and patients treated with an ACEI [209]. Observational data from the same study estimated 
that each 10 mmHg decrease in systolic blood pressure was associated with reduction in risk of 12% for 
any complication related to diabetes (11% for myocardial infarction; 95% CI: 7-14%, p<0.0001) with the 
lowest risk being in those with systolic blood pressure less than 120 mmHg [210]. 
 
Table 2.5. Blood pressure-lowering randomized controlled trials in hypertensive patients with T2DM  
                 
  Pub. Duration No. of Age
§
 Male BMI
§
 T2DM (yrs) History of Intervention form sBP/dBP
§
 sBP/dBP
§
 RRR% in major % improvement  
  year (years) patients   (%)  duration§ CVD (%)   baseline follow-up CV events sBP dBP  
UKPDS-HDS
197
 1998 8.4 1148 56 54 30 2.6 0 Captopril/Atenolol (C/A) 160/94 C/A:144/82 34 in favour of C/A** 10 13  
                  vs other drugs (O)   O:154/87 (p=0.019)      
HOT
207*
 1998 3.7 1501 62 53 28 NA 6 Felodipine (intensive) vs Felodipine 170/105 1:144/85 29 (1 vs 2) 15 19  
               1:≤90 mmHg;     2:141/83 18 (2 vs 3) 17 21  
                 2:≤85 mmHg;   3:140/81 47 (1 vs 3) 18 23  
                  3:≤80 mmHg     (all p<0.05)      
SHEP
200*
 1996 4.5 583 72 43 NA NA 5 Chlorthalidone/Atenolol/Reserpine (I) 170/77 I:143/68 34 in favour of I 16 12  
                  vs placebo (C)   C:155/72 (p<0.05)      
Syst-Eur
201*
 1999 2.0 492 70 26 NA NA 30 Nitrendipine/Enalapril/Hydrochlor- 175/85 I:153/76 69 in favour of I 13 11  
                 thiazide (I) vs Placebo (C)   C:162/81 (p<0.05)      
CAPPP
202*
 2001 6.1 572 55 62 31 8.7 10 Captopril (C)vs Diuretics/ 163/97 
 
C:156/89 33 in favour of C*** 4 8  
                  Beta-blockers (D/B)   D/B:154/88 (p=0.03)      
FACET
199
 1998 2.8 380 63 60 NA 10.6 NA Fosinopril (F) vs Amlodipin (A) vs  171/95 F:157/88 51 in favour of F 8 7  
                  Fosinopril/Amlodipin   A:153/86 (p=0.03)      
ABCD
198
 1998 5.0 470 58 68 32 8.7 27 Enalapril (E) vs Nisoldipine (N) 156/98 E:135/78 9 (in favour of E) 14 20  
                      N:135/78        
STOP-2
203*
 2000 2.0 719 76 40 28 NA 15 ACEI (A) vs Felodipine/Isradipine (FI) 195/96 A:160/80 49 (A vs CA)† 18 17  
                vs Diuretics/beta-blockers (C)   CA:161/78 (p=0.025)      
                      C:161/80        
INSIGHT
204*
 2003 3.0 1302 60 48 NA NA 7 Nefidipine (N) vs Co-Amilozide (C) 175/98 N:145/82 24 (in favour of N)†† 17 16  
                      C:144/82 (p=0.03)      
LIFE
205*
 2002 4.7 1195 67 47 30 NA 24 Losartan (L) vs Atenolol (A) 177/96 L:146/79 24 in favour of L 18 18  
                      A:148/79 (p=0.03)      
ALLHAT
206*
 2005 4.9 13101 67 51 31 NA 36 Chlorthalidone (C) vs Amlodipine 147/83 C:135/74 NS††† 8 11  
                (A) vs Lisinopril (L)   A:136/74        
                  L:138/75        
ASCOT-BPLA
208*
 2005 5.5 5145 63 77 29 NA 0 Amlodipine based regimen (AM) vs 164/95 AM:138/77 13 (in favour of AM) 16 22  
                  Atenolol based regimen (AT)   AT:138/79 (p=0.03)      
§
 Mean values 
* 
Sub group analyses of larger trials     
** Combined macrovascular end point including: myocardial infarction, sudden death, stroke and peripheral vascular disease in favour of strict control. No difference in  
in mortality and/or microvascular disease between Captopril and Atenolol found in sub study.     
*** RRR in all myocardial infarction of 66% in favour of Captopril     
† all myocardial infarction     
†† secondary outcomes (combined cardiovascular death, MI, CHF and stroke (primary outcome), all-cause mortality and death from vascular and non-vascular causes)  
††† increased incidence of congestive heart failure (relative risk, 1.39 [95% CI, 1.22-1.59], p=0.001) for those assigned to amlodipine compared with chlorthalidone   
except from the RRR that represent total cardiovascular events, all data based on the total population     
RRR, relative risk reduction; NA, not available; sBP, systolic blood pressure; dBP, diastolic blood pressure; Ca-A, Calcium-channel antagonist; NS, no statistical difference    
Pub. year, year of publication     
 
The importance of lowering the diastolic blood pressure in patients with T2DM was shown in the 
Hypertension Optimal Treatment study (HOT) where a diastolic blood pressure below 80 mmHg halved 
the incidence of major cardiovascular events compared to patients with a target diastolic blood pressure 
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of 90 mmHg (table 2.5) [207]. Thus clinical trials [196,206] and observational studies [210] emphasize 
the need for tight blood pressure control in patients with T2DM and hypertension. The question of how 
far and in what way the blood pressure should be lowered in patients with T2DM is highly relevant and 
several reviews and meta-analyses have addressed this issue [211,212]. Different advisory boards have 
chosen to recommend a relatively strict blood pressure control below 130/85 mmHg [213,214] and other 
boards recommend a treatment target below 130/80 mmHg and below 120/70 mmHg in patients with 
albuminuria [215,216]. These recommendations are based partly on epidemiological studies and meta-
analyses [210-212] since none of the randomized controlled trials listed in table 2.5 reached the 
recommended treatment target or were close in doing so [197,201,203]. The latest statement is, that 
lowering of the blood pressure seems to be the essential part for CVD prevention rather than the drug 
classes used to achieve it [212] but the evidence is not unified. In the Heart Outcomes Prevention 
Evaluation study (HOPE) an ACEI or placebo were administrated to high-risk patients with a history of 
IHD, stroke, PAD or T2DM, and at least one additionally cardiovascular risk factor [217]. A total of 3577 
patients with T2DM were included, of whom 1135 had no clinical signs of CVD. Nearly one-third of the 
patients had microalbuminuria and 56% had a history of hypertension. Baseline blood pressure was 
142/80 mmHg and despite a mean reduction in blood pressure of only 3/2 mmHg in the intervention 
group, treatment with an ACEI for 4 years significantly reduced deaths from cardiovascular disease and 
stroke. The decreased risks of MI and stroke were similar to those seen in the UKPDS, where the mean 
difference in blood pressure was 10/5 mmHg between the two groups (table 2.5) [197]. 
The ACEIs may possess beneficial effects on the cardiovascular system that is beyond the 
blood pressure lowering effect. The size of this effect may be dependent of concomitant diseases. The 
choice of antihypertensive agent should therefore be individualized and guided by the presence of 
concomitant clinical disease and the need to protect any specific target organ system. In overt 
nephropathy, it is recommendable to start or supply the antihypertensive therapy with an angiotensin 
receptor-II antagonist (ARA), which in several studies have shown to be very beneficial in slowing the 
progression to end stage renal disease in hypertensive patients with T2DM [218-220]. To reduce left-
ventricular hypertrophy, ACEI or calcium-channel antagonists seems superior to both diuretics and beta-
blockers [221,222] and in the presence of congestive heart failure, calcium-channel blockers are relatively 
contraintradicted [206,212]. But hypertensive patients with T2DM often need multiple drugs to reach 
treatment goal. After 8 years in the UKPDS, nearly 30% of the patients in the intensively treated group 
needed 3 or more antihypertensive drugs to reach and maintain a mean blood pressure of 144/82 mmHg 
[197]. In the same study, almost 40% needed at least 2 drugs to maintain target and still the obtained 
mean blood pressure was relatively far from current recommendations (table 2.5). Looking at the 
metabolic effect of the antihypertensive agents in preventing the development of T2DM in high-risk 
patients, treatment strategies are further challenged. Beta-blockers and thiazide diuretics are considered 
metabolically inappropriate, calcium-channel blockers as neutral and ACEI and ARA maybe even 
metabolically beneficial [223,224]. 
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In conclusion, there is substantial data supporting the great impact on cardiovascular events by 
lowering the blood pressure in hypertensive patients with T2DM. The risk reduction may depend upon the 
starting point, but a relative risk reduction of major cardiovascular events up to 50% should be expected 
if the blood pressure is lowered 10-20% (table 2.5). There is no data from randomized controlled trials 
that treatment of the blood pressure below 130/80 mmHg, will result in a further reduction in major 
cardiovascular events. 
 
2.7. Treatment of dyslipidemia 
The most common lipid abnormality in patients with T2DM is elevated triglycerides and low HDL-
cholesterol [225]. Although statin therapy mainly reduces LDL-cholesterol, it decreases cardiovascular risk 
in patients with T2DM. Which lipoprotein is the most atherogenic and should be the primary target of 
lipid management in diabetic dyslipidemia is debatable but LDL-cholesterol is a strong predictor of 
cardiovascular events in patients with or without T2DM [226]. Fibrates are known to increase HDL-
cholesterol levels and lower plasma triglycerides and thus seems to be the logical choice in the treatment 
of diabetic dyslipidaemia [227-229]. Statins also reduce the triglyceride level in patients with T2DM [230] 
and have shown beneficial effects in doing so in several randomized controlled trials [231-241]. Table 2.6 
summarises trials addressing the impact of major cardiovascular outcome in patients with T2DM treated 
with a statin compared to placebo. Many of the trials are based upon sub group analyses of larger trials 
but T2DM patients show similar or greater cardiovascular benefit from statin-based therapy compared 
with overall study populations [231-234,236,238,239,241]. After a coronary event, patients with T2DM 
have a two- to threefold higher risk of a second coronary event [99,242]. It is estimated that patients 
with T2DM and established IHD have a 50% incidence of recurrent MI over 7 years [243]. Even though 
clinical trials often include carefully selected patients, primary prevention trials as the Heart Protection 
Study (HPS) [233] and the Collaborative AtoRvastatin Diabetes Study (CARDS) [235] further showed that 
it may be equally important to initiate statin-based treatment in T2DM patients at a lower cardiovascular 
risk threshold than is recommended by several advisory boards [244,245]. 
Unlike some of the studies concerning treatment of hypertension in patients with T2DM 
[197,207], the statin trials in table 2.6 do not entirely answer the question of what lipid level should be 
targeted although statin therapy was equally effective in patients with high and low plasma LDL-
cholesterol levels in the HPS [233]. However after 2 years of treatment in the PRavastatin or atOrVastatin 
Evaluation and Infection – Thrombolysis in myocardial infarction 22 investigators study (PROVE-IT), a 
composite cardiovascular endpoint was reduced by 16% (p<0.005) in acute coronary patients receiving 
atorvastatin in doses of 80 mg/day (mean attained LDL-cholesterol level: 1.60 mmol/l) compared to the 
patients receiving 40 mg pravastatin per day (mean attained LDL-cholesterol level: 2.46 mmol/l) [246]. 
Patients with T2DM in the study constituted 25% and they received the same cardiovascular benefit from 
aggressive lowering of the LDL-cholesterol. Based upon the randomized controlled trials and epi-
demiological studies, it has been estimated that in the over all population, every 0.78 mmol/l change in 
the LDL-cholesterol concentration will reduce the relative risk for CVD by about 30% [99]. 
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A meta-analysis of lipid-lowering trials based on 10 trials (79 494 patients with and without T2DM) 
showed that statin treatment of the overall population reduced major cardiovascular events by 27% 
(p<0.05) [247]. A separate analysis of the trials with available access to outcome data 
[230,233,235,237], showed a reduction in major cardiovascular events of 19% in patients with T2DM  
 
Table 2.6. Lipid-lowering randomized controlled trials using statins in patients with T2DM 
                            
  Pub. Study No. of Age
§
 Male Study T2DM (yrs) History of Intervention form End LDL End LDL %RRR in major %  
  year duration patients   (%) type duration§ CVD (%) vs placebo Intervention§ Placebo§ CV events  improvement  
AFCAPS/TexCAPS
231*
 1998 5.2 155 58 85 P NA 0  Lovastatin 2.97 4.03 NS**  24  
                  20-40 mg/day          
ALLHAT-LLT
232*
 2002 4.8 3638 66 51 P NA 14  Pravastatin† 2.72 3.34 NS 19  
                   20 mg/day          
HPS
233*
 2003 5.4 2912 62 70 P 9.3 0  Simvastatin 2.30 3.31 33% (p=0.0003) 28  
(10% T1DM)     2426     S   45  40 mg/day     27% (p=0.0007)    
ASCOT-LLA
234*
 2005 3.3 2532 64 76 P NA 0  Atorvastatin 2.15 3.02 NS†† 35  
                   10 mg/day          
CARDS
235
 2004 3.9 2838 62 68 P 7.9 0  Atorvastatin 2.11 3.12 37% 30  
                  10 mg/day     (p=0.001)    
4S
236*
 1997 5.4 202 60 72 S NA 100  Simvastatin 3.03  4.81 55% 36  
                   40 mg/day     (p=0.002)    
CARE
237
 1998 5.0 586 61 80 S NA 25  Pravastatin 2.53 3.59 25% 28  
                    40 mg/day     (p=0.05)    
LIPID
238*
 2003 6.1 782 64 81 S NA 100  Pravastatin 2.92 3.88 21%***  21  
(2.6% T1DM)                  40 mg/day     (p<0.008)    
LIPS
239*
 2005 3.5 202 63 80 S NA 100  Fluvastatin 2.46 3.80 51%††† 24  
                   80 mg/day     (p=0.0088)    
Post-CABG
240
 1999 4.3 120 63 85 S NA 100  Lovastatin
¥
 2.40 3.52 NS 39  
                   20-40 mg/d          
PROSPER
241*
 2002 3.2 397 75 48 P NA 0  Pravastatin 2.77 3.78 NS 23  
      228     S      40 mg/day          
§
 Mean value 
*
Sub group analyses of larger trials                      
** lovastatin reduced the incidence of first acute major coronary events by 37% (95%; CI: 0.50-0.79, p<0.001) in all patients    
*** denotes RRR for any cardiovascular event. The RRR of major cardiovascular events of 19% did not reach statistical significance (p=0.11)   
† statin treatment allowed in control arm            
†† using an expanded cardiovascular endpoint as major cardiovascular events + procedures a RRR of 23% (p=0.0036) was obtained   
††† reduction of major adverse cardiac events           
¥
 aggressive cholesterol-lowering (± cholesterymin) versus moderate lowering and low-dose warfarin versus placebo.    
RRR, relative risk reduction; NA, data not available; NS, not statistical significant; P, primary prevention study; S, secondary prevention study   
 
(p<0.05) [247]. Another meta-analysis exclusively focusing on the lipid-lowering effect on diabetes 
included 6 primary prevention trials and 8 secondary prevention trials and showed a relative risk 
reduction in cardiovascular events of 22% and 24%, respectively [248]. This analysis also allowed the 
inclusion of 2 fibrate-based studies [227,249]. Based on observational studies [227,250], and upon the 
fact that patients with T2DM who receive primary prevention often are at an advanced stage of 
atherosclerosis, the National Cholesterol Education Program (NCEP) has recently suggested an even 
lower treatment goal of LDL-cholesterol to below 1.81 mmol/l in some high-risk patients with CVD exem-
plified by the patients with T2DM and high-risk of recurrent episodes of IHD [251]. Both the NCEP and 
the ADA agree upon the recommendations that patients with T2DM and CVD should initiate statin 
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treatment regardless of baseline LDL-cholesterol levels. In patients with T2DM and no overt CVD having a 
LDL cholesterol level below 3.0 mmol/l, statin treatment should be based on the clinical situation [251]. 
In conclusion, lowering the LDL-cholesterol to a level between 2.30-3.00 mmol/l, as part 
of primary or secondary prevention in patients with T2DM, induces a relative risk reduction in major 
cardiovascular events of 20-35% (table 2.6). 
 
2.8. Integrated care in the settings of CR 
Little is known of the effect of CR in patients with T2DM in both exercise-based CR and comprehensive 
CR. No prospective randomized controlled trials exclusively examining the effect of CR in patients with 
T2DM have ever been performed and in the meta-analyses shown in table 2.7, no separate outcome 
analyses are available for the patients with T2DM [30-32,252,253]. The patients taking insulin had also 
often been excluded from the clinical trials finally included in the meta-analyses. 
 
Table 2.7. Effect of CR on mortality based on meta-analyses of clinical controlled trials  
        
  Publication Number of trials Number of Patient RRR% in mortality  
  year included patients category All-cause Cardiac  
Oldridge et al30 1988 19 4347 post-MI 24
* NS  
O'Connor et al32 1989 22 4554 post-MI 20
* 22*  
Joliffe et al252 2000 32 8440 post-MI + IHD 27
* 31*  
Brown et al253 2003 46 8677 post-MI + IHD      
     Exercise-based    2984   24
* 27*  
     Comprehensive CR    5693   NS 20
*  
Taylor et al31 2004 48 8940 post-MI + IHD 20
* 26*  
MI, myocardial infarction; IHD, ischemic heart disease (also revascularizations and stable angina); RRR, relative risk reduction         
* p<0.05        
 
The results from the meta-analyses clearly show that CR reduces cardiovascular and all-cause mortality in 
the overall population compared to non-attendants. The earlier analyses mainly included exercise-based 
trials [30,32], while the recently performed also allowed comprehensive CR programmes to be included 
[31,252,253]. The meta-analyses have also shown that the attendants in CR programmes obtain a 
significantly reduction in lipids [21,252,253], systolic blood pressure and in smoking [31] compared to 
usual care. 
Only a few not randomized studies have looked upon the effect of exercise-based and 
comprehensive CR programmes in patients with T2DM as a sub group [26,35,55,56,254]. Looking at the 
changes in classical cardiovascular risk factors as lipid profile, blood pressure, exercise capacity and 
depression, these studies do not agree. In one study, 59 patients with T2DM were enrolled in a 2-months 
comprehensive CR programme after an acute coronary event [254]. The improvement in exercise 
capacity was significantly less in patients with T2DM compared to their metabolic normal counterparts. 
The patients with T2DM showed lower levels of peak workload, duration of exercise test, maximal heart 
rate and anaerobic threshold compared to the patients with NGT having similar left ventricular ejection 
fraction and class of MI. No information was given about the effect on other risk factors in this study but 
an important observation was, that the response to the exercise seemed to be influenced by their 
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glycaemic control more than their BMI [254]. In another study offering comprehensive CR to 1505 
patients, the patients with T2DM (19%) benefited the same in improving traditional cardiovascular risk 
factors as the patients with NGT [56]. Both groups obtained the same percentage improvement in lipids, 
and exercise capacity but fewer patients with T2DM achieved the predefined treatment goals, probably 
because of more deteriorated baseline values. 
In conclusion from this review, there is an abundance of evidence-based documentation 
that intensive treatment of single factors as arterial hypertension, dyslipidaemia and smoking in patients 
with T2DM reduces cardiovascular morbidity and mortality. Although limited data addressing the effect of 
CR in patients with T2DM or IGT, CR has shown itself to be highly effective in reducing mortality in the 
overall population. The DANSUK study was therefore designed to address this issue by assessing the 
effectiveness of participation in a comprehensive CR programme on clinical outcome in patients with 
T2DM or IGT compared to usual care. It was hypothesized that treatment goals would be reached to a 
higher degree in these patients, if focus was brought upon glucometabolic abnormalities and if the 
metabolic care became an integrated part of the comprehensive CR. Beside behavioural modification, the 
DANSUK study should also focus on the use of combined evidence-based medical therapies with the 
potentiality of a synergistic benefit in these patients. 
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Part II: The DANSUK study 
3. Background and design (the book chapter, appendix 1) 
3.1. Background 
Although much of the literature is before the year of 2000, international research has documented that 
cardiac rehabilitation (CR) improves quality of life and survival rates among patients with cardiovascular 
diseases [30-32,255]. Bispebjerg University Hospital has a catchment area of nearly 140.000 individuals 
making it one of the largest hospitals in Denmark. As part of being selected as a model hospital for health 
promotion, the department of cardiology at Bispebjerg University Hospital developed a comprehensive, 
integrated CR programme in 1997. The CR programme was based on the guidelines of the Danish Heart 
Foundation and the Danish Society of Cardiology [256]. To test the programme, the randomized con-
trolled DANish cardiac REHABilitation (DANREHAB) trial was carried out with inclusion of 770 patients 
over 3 years in the period of 2000 to 2003 [257]. The aims of the DANREHAB trial were to investigate 
whether a comprehensive, integrated CR programme at a hospital-based outpatient clinic had an imme-
diate and long-term effect on morbidity and mortality compared to usual care in patients discharged from 
a department of cardiology. The primary endpoint after 12 months were the combined endpoint of overall 
mortality, non-fatal re-infarctions, readmissions due to ischemic heart disease (IHD), congestive heart 
failure (CHF) or other cardiovascular diseases (CVD). Secondary endpoints after 12 months were overall 
mortality, acute ischemic syndrome, deterioration of CHF and total readmission rate. Tertiary endpoints 
after 12 months were quality of life, lifestyle changes, changes in risk factor control and uses of social 
services. Register based investigation of all cause mortality, causes of deaths, number and causes of 
readmissions will be performed after 5 and 8 years [257]. 
During the first two years of inclusion in the DANREHAB trial, 20% of the 569 patients 
enrolled were registered as having diabetes at baseline. Due to publication of sensational studies during 
study period an increased focus on T2DM and its precursors arose [103,104,106,204,205,217,233]. The 
DANSUK sub study was therefore designed to examine the patients included within the last year of the 
DANREHAB trial for unrecognized type 2 diabetes (T2DM), impaired glucose tolerance (IGT) and impaired 
fasting glucose (IFG) (DANSUK 1) [258]. Another aim of the sub study was to develop and integrate a 
diabetes module into the settings of comprehensive CR and to optimize the intensive risk factor control in 
patients with T2DM or IGT comparing the outcome with usual care (DANSUK 2) [259]. 
 
3.2. Design and endpoints 
The DANREHAB study was designed as a two-armed centrally randomized clinical trial comparing hos-
pital-based CR to usual care (UC). Patients from the department of cardiology at Bispebjerg University 
Hospital with IHD, CHF or high-risk (HR) of ischemic heart disease with at least 3 classical cardiovascular 
risk factors were consecutively screened for eligibility. There was no age limit for participation but only 
patients living at home were eligible. Other exclusion criteria were severe non-cardiovascular disease, 
NYHA stage IV, unstable patients awaiting revascularisation, severe abuse of alcohol and sedatives, 
dementia, and linguistic problems. Consenters were randomized 1:1 to CR or UC using a centralized 
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randomization procedure with stratification according to cardiac diagnosis group, age, gender and history 
of T2DM. In the last year of the DANREHAB study, 201 patients were included and randomized and 
became also a part of the DANSUK study (figure 3.1.). 
 
 
 
Besides the determination of the prevalence of IGM among patients eligible for CR, the primary objective 
of the DANSUK study was to evaluate if an intensified integrated approach of treatment would result in a 
better glycaemic control measured by differences in HbA1c compared to usual cardiac and diabetic re-
gimes. Differences in blood pressure, lipid control, exercise capacity and other life style modifications 
were secondary objectives. 
 
3.3. Classifying IGM 
Classification of impaired glucose metabolism (IGM) was based on known type 2 diabetes (KT2DM) at 
baseline or by the performance of a standardised 75-gram oral glucose tolerance test (OGTT) after 3 
months of follow-up in the remaining population invited independently of the randomization. Blood 
glucose was measured fasting, and after 120 minutes. Based on the outcome of the OGTT and two 
fasting glucose values the patients were divided into 4 groups according to the WHO definitions of 
glucometabolic disturbances [85] (figure 3.2.). The patients were informed of the restrictions they had to 
undertake prior to the test [258]. The patients diagnosed with isolated IFG did not undergo the inten-
sified metabolic care but participated in the comprehensive CR programme like the patients with NGT. 
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3.4. Comprehensive cardiac rehabilitation 
The 12 months of CR was constructed according to international guidelines and was individually tailored 
[256,257]. The first six weeks of the CR programme contained elements of patients education, super-
vised exercise training, dietary counselling and supervised cooking lessons on location, smoking cessa-
tion, psycho-social support including a 24-hour telephone line, pharmacological therapy and risk factor 
management supported by a minimum of consultations by a physician after 3, 6 and 12 months (figure 
3.3). A team of doctors and nurses trained in internal medicine and cardiology treated the patients in the 
CR group. Other members of the team were dieticians, physical therapists, social workers, and psychia-
trists. Patients randomized to CR were grouped and accompanied each other throughout the 6 weeks of 
lectures and physical training. The six weeks of supervised exercise training consisted of 90 minutes of 
training twice a week aiming at an intensity of 60% to 85% of maximal heart rate based on an initial 
symptom limited bicycle test. The training plan was highly individualized and the patients were monitored 
clinically in terms of cardiopulmonary response to the exercise and by the use of pulse watches. The 
physical exercise was conducted as a mixture of endurance and strengthening training using various up-
per and lower body modalities easily implemented as activities that the patients could perform at home. 
Rating on Borg’s scale was used since it have been found to relate closely to other objective measures of 
exercise intensity such as oxygen uptake and heart rate [260]. Adherence to the advised increased level 
of physical activity was registered by validated self-administrated questionnaires, interviews and maximal 
bicycle exercise capacity tests after 3 and 12 months [261-267]. Adherence to other behavioral modi-
fication was also registered by questionnaires and interviews [257]. 
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3.5. The diabetes module – The DANSUK study 
T2DM is a chronic disease that requires ongoing care tailored to the needs of the patient. In the process 
of integrating the diabetes module in the overall comprehensive CR programme, the same life style 
intervention models as the health belief model were used [268]. In the DANSUK study, patient education 
formed the framework on which intensive medication, nutrition, and other lifestyle modifications were 
built. Besides ensuring that all the patients eligible to CR underwent a proper screening for IGM, the aims 
of the diabetes module were to combine systematic risk factor management of diabetic and cardiovascu-
lar complications in the overall rehabilitation by means of increasing patient adherence to physician-
defined therapeutic goals and treatment strategies and to optimize active participation by patients 
through motivation and increased knowledge. 
 
 
Intensive rehabilitation 
 
 
Programme: 
• Physical exercise 
• Patient education 
• Psycho-social support 
• Nutritional counselling 
• Smoking secession 
• Pharmacological therapy 
• Follow-up by physician 
 
Individually tailored 
programme of CR 
 
Consultations: 
• Physician 
• Physiotherapist 
• Dietician 
• Nurse 
 
Follow-up 
 
 
Assessments: 
• Physician 
• Nurse 
• Physiotherapist 
• Dietician 
• Psychiatrist  
• Social worker 
1 week after discharge 6 weeks of intensive CR 3, 6 og 12 months 
Diabetes module 
 
• Individual diabetes consultations 
• Patient education in T2DM 
• Patient education in IGT 
 
 
 
Patients with T2DM were gathered in groups and the diabetes module was implemented as a complete 
integrated part of the CR programme. The diabetes module was highly individualized to consider the 
appropriate intervention needs for different age groups, cardiac disease, duration of T2DM, self-care 
facilities, and severity of complications. Besides individual counselling in blood sugar measurements, the 
use of oral hypoglycaemic agents and adjustments of insulin doses, the diabetes module consisted of 3 
interactive teaching sessions of 2½ hours each with focus on self-care principles involving symptoms of 
peripheral arterial disease (PAD), diabetic neuropathy, nephropathy and retinopathy. Regular surveillance 
by ophthalmologists and chiropodist was ensured for the patients. The programme was build up to 
emphasize the critical link between T2DM and IHD because of the crucial need for the patients truly to 
Figure 3.3. Patient flow throughout the study period showing the different components of the comprehensive CR 
programme and the supplementary diabetes module that became an integrated part 
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understand the implications of T2DM on their cardiovascular health. Patients with newly diagnosed IGT 
were invited to a two-hour session with recommendations of further prophylactic initiatives to prevent the 
development of T2DM. No special exercise prescription and programming were developed for patients 
with T2DM although caution in patients with severe retinopathy or autonomic neuropathy was under-
taken. The patients were informed of the immediate and long-term effects of exercise on improved 
glycaemia and the risk of exercise-induced hypoglycaemia. The diabetes module was organized to cover 
the whole range of care provision required to achieve the intensified goals of treatment. Patients with 
T2DM were encouraged to use a glucometer and on a regular basis each patient’s monitoring technique 
and interpretation of data was evaluated [267]. 
 
4. Methods 
4.1. Data collection 
The data collection was comprehensive as part of the great DANREHAB trial [257]. Data collected as part 
of the DANSUK study is given in table 4.1. Examinations were done over two consecutively days and the 
patients received oral and written information prior to the tests. The time for all the assessment visits 
were computerized, so when an assessment visit was near by, the patients data appeared on screen in 
the database. Data on diabetic neuropathy (autonomic nervous function, peripheral nervous function), 
fundus photographs and measurement obtained by echocardiography and spirometry will not be 
described in details, as it is not within the frames of this dissertation. 
 
Anthropometric measurements 
Weight was measured to the nearest 0.1 kg and with the patient wearing indoor clothing without shoes. 
Height was measured to the nearest 0.5 cm with the patient wearing no shoes. Body mass index (BMI) 
was calculated as weight in kilograms divided by the square of heights in meters [269]. With the patients 
standing in a resting position, waist circumference was measured midway between the iliac crest and the 
costal margin. Hip circumference was measured at its maximum. Waist and hip circumference were 
measured to the nearest 0.5 cm and used in calculation of the waist-hip-ratio. 
 
Blood pressure 
Several blood pressure measurement were done using a standard sphygmomanometer and with the 
patient in both supine and sitting position after 10 minutes of resting. The mean of the last two 
measurements on each arm was used. Ambulatory blood pressure measurement was done at baseline 
and after 12 months with measurements taken every 15 minutes in the daytime and every half hour in 
the nights. 
 
Ankle-brachial pressure index 
The ankle-brachial pressure index (ABPI) was measured in all patients at baseline using the Doppler 
method. For ABPI assessment, the systolic pressure on both arms was measured by auscultation. The 
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Table 4.1. Data collection in the DANSUK study 
     
 0 3 6* 12 
  Baseline months months months 
Fasting plasma glucose x x x x 
HbA1c x x x x 
Fasting-C-peptide x    
Fasting plasma insulin x   x 
Oral Glucose Tolerance Test   x  (x) 
Lipidprofile x x x x 
Standard blood tests  x x x x 
Frozen plasma 1 x x  x 
Resting 12-lead ECG x x x x 
E/I-ratio/Valsalva-ratio 2 x    
Orthostatic hypotension test x    
Ambulatory blood pressure x   x 
Morning spot urine x x  x 
Echocardiography 3 x    
Lung function test x   x 
Exercise stress test x x  x 
Ankle/brachial pressure index x    
Peripheral neuropathy 4 x    
Medication (registration) x   x 
Questionnaires 5 x x x x 
* Data collected only in patients assigned to cardiac rehabilitation  
(x): Repeated in patients primarily diagnosed with IGT   
1 For future analyses of inflammatory markers and cardiac hormones 
2 Heart rate response to deep breating (Ex- and Inspiration) and the valsalva manoevre 
3 Transthoracal with measurements of various systolic and diastolic parametres 
4 Semmes-Weinstein's monofilament/10 g    
5 Validated questionnaires concerning patient satisfaction, depression, quality of life and 
  behavioural modifications    
 
blood pressure above the ankle was assessed on both lower extremities by applying a standard 
tonometer cuff to the leg above the ankles. The cuff was inflated above the expected systolic pressure 
and the pressure was slowly reduced. During the decline of pressure in the cuff the pulsating flow was 
restored and the volume of the leg increased and at that precise moment the systolic pressure was 
measured and registered. The pressure was registered primarily using the posterior tibial artery or if pul-
sation was absent, the dorsalis pedis artery. The pressure was measured twice for each extremity and 
the highest obtainable pressure was used in the calculation of the ABPI. Peripheral artery disease was 
defined as an ABPI of 0.9 or less [270]. 
 
Blood samples 
Blood samples were taken in the morning after an overnight fast. Plasma glucose was determined by the 
hexokinase/G6P-DH method [271]. Few of the glucose concentrations were measured on capillary whole 
blood and converted to venous plasma glucose by means of a conversion factor (fasting plasma glucose = 
0.102 + 1.066 x capillary whole blood glucose) established by the European Epidemiology Group [272]. 
HbA1c and plasma insulin were measured with commercial kits. Normal range: HbA1c 4.1-6.4% and 
plasma insulin 5-69 pmol/l) [273]. Serum cholesterol and HDL cholesterol were analysed by chromatogra-
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phy and triglycerides by colorimetry [274]. VLDL and LDL cholesterol was calculated using the Friedwald’s 
Equation in patients with a serum triglyceride concentration lower than 4 mmol/l  [275]. The OGTT was 
given as 75 g of glucose dissolved in 200 ml of water and was performed on capillary blood. Blood 
samples for later analyses were immediately put on ice and spun within 60 minutes of sampling. Samples 
were hereafter stored frozen at –80°C. 
 
Electrocardiography (ECG) and exercise stress testing 
A 12-lead resting ECG was taken as a minimum of three times for later analysis of myocardial ischemia. 
Exercise stress testing was performed with a bicycle ergometer beginning at 25 Watt and increasing 
workload with 25 Watt at every second minute. In the patients whose latest admission was due to 
congestive heart failure, the workload increased with 10 Watt every minute. 
 
Urine samples 
At baseline and after 3 and 12 months of follow up patients delivered a first morning spot urine sample 
which has been demonstrated to correlate with the 24-hour urinary excretion rate [276,277]. Urine-albu-
min was determined turbidimetrically, and urine-creatinine was determined by creatinine Jaffé method. 
 
Interviews and questionnaires 
In terms of evaluation of non-pharmacological therapy, care management program, adherence to be-
havioural modification etc., the patients were interviewed and received self-completion questionnaires 
during the study period (table 4.1). Only the interviews and questionnaires evaluating the level of 
physical activity and smoking cessation are within the frames of this dissertation. 
 
Ethics 
The examinations of both study groups were obtained at the same place in the unit of CR, at the 
department of cardiology and at the department of biochemistry at Bispebjerg University Hospital. The 
patients randomized to usual care were told that they would be contacted after 3 and 12 months to 
follow-up assessments. Test results collected at the assessments visits were accessible in records, and on 
request the patients randomized to usual care could receive copies to bring about to their physician. All 
patients gave a written consent before taking part in the study. The study was approved by the Scientific 
Ethical Committee of Copenhagen (j.no.(KF) 11 – 121/01). 
 
4.2. Definitions 
Glucometabolic abnormalities 
Impaired glucose metabolism (IGM) was defined using internationally accepted criteria: the WHO from 
1999 [85] and the criteria from the ADA from 2003 [84] (table 4.2.). Patients with previously established 
diagnosis of T2DM, being on a diet or currently taking any form of hypoglycaemic drugs or insulin were 
categorized as KT2DM. In the DANSUK study it was decided to let all the patients with no history of 
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T2DM undergo a standardised OGTT [85]. Diagnosing IGT was part of the study objective as classifica-
tion based on FPG alone has been shown to leave 31% of all patients with T2DM undiagnosed [272]. 
 
Cardiac disease groups 
Definitions of myocardial infarction and congestive heart failure used internationally accepted criteria 
[278,279]. The patients were divided into one of three stratification groups: The IHD group defined 
patients who had known IHD prior to admission or who were admitted because of an acute MI. The 
patients stratified into the CHF group were patients whose latest admission was due to congestive heart 
failure. The group of high-risk for IHD (the HR group) were patients with at least 3 classical cardiovas-
cular risk factors [257]. 
 
Table 4.2. The diagnostic criteria for impaired glucose metabolism used in the DANSUK study according to the 
WHO and the ADA definitions [84,85] 
   
Glucose Tolerance Fasting plasma glucose 
*    2 hours capillary glucose 
Normal glucose tolerance (WHO)  ≤ 6.0 mmol/L AND < 7.8 mmol/L 
Normal glucose tolerance (ADA)  ≤5. 5 mmol/L   
Impaired fasting glucose (WHO) 6.1-6.9 mmol/L    AND < 7.8 mmol/L 
Impaired fasting glucose (ADA) 5.6-6.9 mmol/L      
Impaired glucose tolerance < 7.0 mmol/L AND 7.8 - 11.0 mmol/L 
Diabetes mellitus ≥ 7.0 mmol/L AND/OR    ≥ 11.1 mmol/L 
* Tests taken on two occasions 
       
 
Family history of diabetes 
A positive family history of diabetes implied either a parent or sibling to have diabetes. 
 
Arterial Hypertension 
Patients were classified as having systemic hypertension if they received medical therapy for hyperten-
sion or if they had two resting blood pressure measurements during hospital admission above 140/90 
mmHg. 
 
Dyslipidaemia 
The patients were diagnosed with dyslipidaemia if they were treated with lipid lowering drugs or if a lipid 
profile taken at admission showed values of total cholesterol above 5.0 mmol/l, HDL cholesterol less than 
1.0 mmol/l, or triglycerides above 1.5 mmol/l [257]. 
 
Albuminuria 
The Urine-albumin-creatinine ratio (mg/mmol) was calculated; normal range < 2.5 mg/mmol. If the mor-
ning spot urine samples had an albumin-creatinine index between 2.5 – 25 mg/mmol at baseline and at 
the 3 months assessment visit, the patients were diagnosed with microalbuminuria and if the value 
exceeded 25 mg/mmol the qualitative diagnosis of macroalbuminuria was definitive [276,277]. 
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Smoking 
Smoking habits were graded as never, ex- or current smoker. At baseline and after 12 months current 
smokers and ex-smokers had their concentration of carbon monoxide in expired air measured. The 
carbon monoxide concentration was measured regularly among patients who had quitted to allow the 
patient to see that this parameter declines as a result of quitting. The patients who wanted to quit 
smoking were offered free accession to nicotine replacement therapy as well as motivated spouses could 
receive replacement therapy for one week free of charge [264]. 
 
Physical activity 
Participants were given a self-completion questionnaire on health related behaviour including physical 
exercise at baseline and after 3 and 6 months. The level of physical activity was divided into 4 groups: 1) 
Almost physical passive responded to active less than 2 hours a week. 2) Moderate physical active for 2-4 
hours a week 3) Moderate physical activity for more than 4 hours a week 4) High physical activity for 
more than 4 hours a week. For later analyses, group 1 and 2 were defined as sedentary life style and 
group 3 and 4 as physically active life style. 
 
Overweight and obesity 
The BMI was used to categorize patients as overweight if they had a BMI from 25.0 kg/m2 to 29.9 kg/m2 
whereas BMI equal to or greater than 30 kg/m2 was defined as obesity [269]. For central obesity waist 
circumference was used as well as the waist-hip-ratio. Different cut-off values have been suggested as 
part of describing the optimal applicable definition of the metabolic syndrome in epidemiological studies 
[280]. In the DANSUK study, waist circumference was considered increased if equal to or greater than 94 
cm in men and equal to or greater than 80 cm in women. 
 
Hyperinsulinemia and insulin resistance 
Insulin resistance (HOMA-IR) as defined by the WHO requires a euglycaemic, hyperinsulinaemic clamp 
performance but as modified according to the European Group for the study of Insulin Resistance (EGIR) 
fasting plasma insulin was used in the DANSUK study [281] even though the use in patients with T2DM is 
questionable. Hyperinsulinemia was defined as the upper quartile of fasting plasma values and insulin 
resistance by the homeostasis model assessment (HOMA) determined in Danish population-based studies 
i.e. cut-off value of hyperinsulinaemia: 51 pmol/l and of HOMA-IR: 1.76 [282,283]. Insulin resistance 
(HOMA-IR) was calculated by: fasting plasma insulin (µU/ml) x FPG (mmol/l) divided by 22.5 [277,278]. 
 
4.3.  Intensive treatment modalities in the unit of CR 
The intensive intervention strategy involved a stepwise introduction of behavioural modification and 
pharmacotherapy aiming to reach the evidence-based treatment goals outlined in table 4.3. The treat-
ment goals should be realistic and feasible within the study period of 12 months. At every individual 
assessment visit in the CR group, measurements were scrutinized thoroughly to see if the goals were 
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obtained and if not which initiative could be installed to accomplished this before the next assessment 
visit. This arrangement was thought only to be feasible if the patients participated and used their self-
care learned principles at their highest. All measurements and treatment goals were written in a personal 
manual kept by the patients controlled and adjusted at every visit. 
 
 
Table 4.3. Intensive treatment goals for patients with type 2 
diabetes or impaired glucose tolerance in the DANSUK study 
    
  Treatment goal 
HbA1C (%) < 6.5 
Fasting plasma glucose (mmol/l) 4.0-7.0 
Post prandial blood glucose (mmol/l) 4.0-8.0 
Systolic blood pressure (mmHg) < 130 [<120] 
Diastolic blood pressure (mmHg) < 80 [<70] 
Total cholesterol (mmol/l) < 4.5 
HDL cholesterol (mmol/l) > 1.1 
LDL cholesterol (mmol/l) < 2.5 
Triglycerides (mmol/l) < 1.7 
Physical exercise > 30 min per day 
Body Mass Index (m2) < 25* 
Functional and psycho social capacity Optimal 
Smoking** Complete secession 
ACEI/ARA irrespective of blood pressure Yes 
ASA irrespective of manifest IHD or PAD Yes 
Statin irrespective of cholesterol levels Yes 
[if macro- or microalbuminuria] * goal setting individualized aimed at loosing 
10-15% of total body weight. Abbreviations: ACEI: Angiotensin-converting 
enzyme inhibitor, ARA: Angiotensin receptor-II antagonist, IHD: Ischemic 
heart disease, PAD: Peripherial arterial disease.  ** Smoking patients and their 
spouses were invited to participate in smoking cessation course 
 
 
 
Pharmacological care 
Glucose-lowering treatment and glucose control 
To achieve the predefined goal of an HbA1c-value below 6.5%, a stepwise approach was used con-
cerning oral hypoglycaemic agents and insulin. As part of the comprehensive treatment algorithm to 
maintain optimal glycaemic control in the patients, many different hypoglycaemic agents were prescribed. 
There was a limited use of thiazolidinediones because of the lack of evidence when used in patients with 
coexisting cardiac diseases. Gliclazid or glimepiride were often chosen as sulfonylureas, because of their 
neutral effect on myocardial K+-channels. Obese patients without a severe degree of congestive heart 
failure were treated with metformin in doses of 1 to 2 g per day. Lean patients were started on 
glimepride in doses of 1-4 mg per day. Second step for obese and lean patients was glimepride and 
metformin respectively. If HbA1c was above 6.5% despite of maximum treatment with oral hypogly-
caemic agents, dietetic restrictions, and physical exercise, patients were given insulin usually NPH insulin 
at nighttime. The type and dose of insulin was adjusted by fasting plasma glucose values and by self-
monitored blood glucose (appendix 2). Arcobase was used in some of the patients in the beginning of the 
study but often discontinued due to gastrointestinal side effects. In the DANSUK study great efforts were 
made in diminishing three aspects of the hyperglycaemic spectrum. The patients were carefully trained in 
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using self-monitored blood glucose and were educated in understanding the importance of trying to 
normalize FPG and postprandial hyperglycaemia as well as minimising glycaemic variabililty (appendix 1 
and 2). Postprandial glucose is known to be an independent risk factor for CVD. But the importance of 
postprandial glucose in the overall glycaemic control increases as HbA1c percentages improves. In 
patients with an HbA1c between 7.3% and 8.3%, postprandial hyperglycemia has been shown to account 
for 50% of the elevated HbA1c [286]. Normalising the postprandial glucose values was therefore as 
important a goal as normalising FPG. To assure as normal glycaemic level as possible throughout the day, 
the patients were given instructions to measure the blood glucose 6 times a day. When diet adherence 
and hypoglycaemic agents were in an optimal steady state the patients could perform a glucose profile of 
6 measurements over 2 consecutively days at every 14th day and depending on their needs [appendix 2]. 
The percentage of patients obtaining an HbA1c level below 6.5% during and at the end of the study was 
used as an indicator of success. Both HbA1c and FPG were used as powerful feedback parameters 
towards the patients to increase the level of motivation, compliance, and adherence to therapy.  
 
Treatment of hypertension and blood pressure control 
Great effort was invested in the combination of the most appropriate therapy in the treatment of arterial 
hypertension. When ever possible long-acting combinations and combination of antihypertensive medica-
tions such as ACEI or ARA combined with a diuretics or a calcium-channel antagonist were preferred to 
improve patient compliance to medication and daily pill count. Figure 4.1 shows an example of a treat-
ment algorithm initiated in the hypertensive patients not using any antihypertensive agents at referral. 
Many of the patients in the DANSUK study were at referral already in some kind of medical treatment due 
to their pre-existing cardiac disease and depending of diagnosis and symptoms, different algorithms were 
created. Thus beta-blockers may be substituted for calcium channel blockers if the patient was in a post-
MI phase, had angina, heart failure or arrhythmia. A nurse controlled blood pressure regularly every 2-3 
weeks using a standard sphygmomanometer until the treatment goal was reached. If there were signs of 
treatment failure, a 24-hour measurement was frequently performed.  
 
Treatment of dyslipidaemia and lipid control 
Therapeutic lifestyle change remains the keystone of lipid management for patients with T2DM requiring 
lipid therapy but in the DANSUK study all the patients with T2DM or IGT in the unit of CR were started 
treatment with a statin early in the study period not awaiting results of nutritional changes or exercise. 
Measurement of adherence to treatment was based on regularly lipid profiles. The use of fibrates in the 
DANSUK study was limited. Patients with T2DM or IGT were treated with a statin, irrespective of the 
values of total cholesterol, LDL cholesterol and HDL cholesterol or history of cardiac disease.  
 
Other pharmacological treatment modalities 
As part of the predefined treatment goals in the DANSUK study (table 4.3), all patients with T2DM or IGT 
in the CR group had to receive treatment with ASA independently of co-existing vascular disease. 
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Blood pressure >130/80 mmHg 
ACEI (alternative ARA if side effects or microalbuminuria) 
Monoxidin was added 
 
Thiazide (or indapamide if clinical signs of oedema) or 
amlodopine-like agent (eventually verapamil/diltiazem if 
tackycard/microalbuminuria and no signs of CHF) was added 
 
Resting pulse > 60/min and/or ABPI > 0.9 
Low-dose beta-blocker (eventually alpha-
beta-blocker) was added 
 
If BP still not at goal 
If BP still not at goal  
Resting pulse < 60/min and/or ABPI < 0.9 
Figure 4.1. Treatment algorithme used in the DANSUK study to obtain the predefined treatment goal 
of arterial hypertension. BP, blood pressure; ACEI, angiotensin-converting enzyme inhibitor; ARA, 
angiotensin receptor-II antagonist; ABPI, ankle/brachial pressure index 
   
 
Patients who had been revascularized involving coronary stenting also received treatment with clopido-
grel. Patients in the CR were all screened for mental depression and were offered medical treatment if 
needed. There was no use of weight loss inducing pharmacological treatment. 
 
Behavioural care and self-care 
Apart from the prescheduled assessment visits, the patients in the CR group could consult the dieticians, 
nurses, physiotherapists and the physicians on request. At these visits the patients received brief sup-
portive advice, reinforcing them to continue their change of lifestyle. At every consultation in the unit of 
CR, smokers were encouraged to give up smoking and the patients were constantly inspired to increase 
the level of physical activity. The physicians were responsibly of emphasizing the significant contribution 
of nutritional counselling and physical exercise towards the patients. Consultation by a dietician is of 
great necessity in patients with T2DM with IHD and has been shown to cause an 8.6% reduction in 
hospitalization and a 16.9% reduction in physician visits [287]. Behavioural changes and adherence to 
pharmacological treatment are essential for improving the prognosis in T2DM patients with or without 
cardiac disease. But T2DM in combination with CVD contains many aspects that make compliance and 
adherence to therapy difficult. Being a chronic disorder, lifestyle changes are required, and the treat-
ment is often complex, intrusive and inconvenient in demanding, besides motivation, some degree of 
self-discipline. Many of the patients took two tablets plus maybe insulin for control of their blood glucose, 
one tablet for dyslipidaemia, and two maybe 3 agents for hypertension, in addition to a low-dose ASA 
and maybe a clopidogrel each day. Thus the need for continued and individualized education and en-
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couragement was in focus throughout the study period to maintain the patients motivated and self-
assured in the hope of increasing adherence to the programme. 
 
4.4. Statistical methods 
All test were made by SAS statistical systems. The power calculation of the DANSUK study was based on 
the primary end point. The mean baseline HbA1c-value in the patients with KT2DM included within the 
first two years of the main study (N = 114) was 8% ± 1.75% [257]. With the intention of reducing the 
mean HbA1c from a mean of 8% to a mean of less than 6.5% over the study period of 1 year, each 
treatment group had to consist of at least 21 patients with T2DM with a power of 80% and a type I error 
of 0.05. Baseline and follow-up characteristics were compared between the groups using t-test for 
continuous variables and X2 test for categorical variables. Results are shown as means ± SD for con-
tinuous variables and as number and percent for categorical variables. Intergroup comparisons were 
made by parred t-test for normally distrubuted variables and by Wilcoxon two-sample test for variables 
with a skewed distribution. Analyses were made separately for men and women when appropriate. 
Verification of normal distribution of data was accomplished with histograms. Kruskal-Wallis test was 
used to test for difference between two or more independent groups in non-parametric data. McNemar’s 
test was used to test changes in pharmacological use from baseline to end of study. For the analyses of 
independent predictors of glucose intolerance two different comparisons were made: T2DM versus NGT 
and IGT versus NGT. Two models were analysed using logistic regression. Model 1 included all predictors 
known at baseline that were significantly related to IGT in bivariate analyses. In model 2, variables 
believed to be mediators or intermediate variables of the relation between predictors and IGT were 
removed (FPG, HbA1c and HOMA-IR). Statistical significance was defined as a two-sided p<0.05. 
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Part III: Prevalence of IGM in the DANSUK study           
5. Results – DANSUK 1 (Article 1, appendix 3)            
5.1. Baseline characteristics of the study population 
The study population comprised 201 patients with a mean age of 62.5 ± 11.0 years. Women constituted 
30% of the patients included. Apart from lipid control, the risk profile was worse in patients with KT2DM 
compared to the patients undergoing screening for IGM (table 5.1). There was no significant difference in 
age and cardiac disease stratification in patients with KT2DM and patients with no previously known 
glucometabolic abnormality. An underutilisation of cardiovascular pharmacotherapy in the patients with 
 
 
Table 5.1. Patients characteristics of the DANSUK study (N = 201) 
 
 
     
  
KT2DM 
N = 42 
Patients to 
screen 
N = 159 P
**  
Demographic         
Age [years/range] 63.5 [42-82] 62.3 [37-89] NS   
Women 38% 28% NS   
Stratification         
Congestive Heart Failure 2 (5) 14 (9) NS   
Ischemic Heart Disease 26 (62) 95 (60) NS   
High-Risk patients 14 (33) 50 (31) NS   
Previous history         
Myocardial Infarction 9 (21) 32 (20) NS   
Revascularization 16 (38) 82 (52) NS   
Known systemic hypertension 31 (74) 85 (53) 0.018   
Known hypercholesterolemia 32 (76) 119 (75) NS   
Cerebrovascular events 7 (17) 20 (13) NS   
Intermittens clautication 8 (19) 20 (13) NS   
Clinical         
Ambulatory systolic blood pressure (mmHg) 131.5 (20.5) 124.9 (18.4) 0.048   
Ambulatory diastolic blood pressure (mmHg) 73.0 (9.2) 73.7 (9.2) NS   
Physical inactive (< 30 min/day) 23 (55) 72 (45) NS   
Body Mass Index (kg/m2) 32.7 (6.9) 28.1 (4.9) 0.001   
Ancle-Brachial Pressure Index < 0.9 16 (38) 36 (23) 0.042   
Exercise capacity (mets) 5.53 (1.0) 6.36 (1.5) 0.004   
Biochemical         
Total cholesterol (mmol/l) 4.17 (1.1) 4.83 (1.1) 0.001   
HDL cholesterol (mmol/l) 1.17 (0.4) 1.31 (0.4) 0.027   
LDL cholesterol (mmol/l) 2.17 (0.9) 2.81 (1.0) 0.0002   
VLDL cholesterol (mmol/l) 0.72 (0.4) 0.67 (0.3) NS   
Triglycerides (mmol/l) 1.83 (1.3) 1.57 (0.9) NS   
Fasting plasma glucose (mmol/l) 8.20 (2.1) 5.91 (1.1) 
< 
0.0001   
HbA1C (%) 7.35 (1.3) 5.95 (0.6) 
< 
0.0001   
Hyperinsulinemia (≥ 51 pmol/l) 26 (62) 76 (48) NS   
Microalbuminuria (2,5-25 mg/mmol) 11 (26) 14 (9) < 0.002   
Cardiovascular medication        
ASA 29 (69) 120 (75) NS   
ACEI/ARA 20 (47) 59 (37) NS   
β-blockers 19 (45) 78 (62) NS   
Statins 31 (74) 99 (62) NS   
Mean values or exact numbers. Brackets are 1 SD or %. KT2DM, known type 2 diabetes at 
baseline, ACEI, converting enzyme inhibitor, ARA, angiotensin receptor-II antagonist 
** p values for difference between groups   
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T2DM compared to the patients with no previously glucometabolic abnormality, was not observed. Table 
5.2 shows baseline characteristics of the patients sub grouped by the result of the OGTT and FPG values. 
A worsening of the risk profile followed increasing disturbance in glucose metabolism. The fasting values 
of plasma C-peptide and insulin were also markedly higher in patients with glucose intolerance although 
nearly one third of the patients with a normal glucose metabolism were hyperinsulinemic compared to 
the background population. As the glucose tolerance deteriorates, values of fasting plasma insulin tends 
to decrease as a manifestation of failing beta-cell function. 
 
Table 5.2. Baseline characteristics in patients sub grouped by outcome of an oral glucose tolerance test   
        
The DANSUK study (N = 201) 
 
KT2DM 
N = 42 
 
ST2DM 
N = 26 
IGT 
N = 36 
IFG 
N = 19 
NGT 
N = 78 P**   
Demographic               
Age (years*/range) 63.5 (42-82) 63.4 (50-81) 64.8 (45-89) 63.2 (50-80) 60.5 (37-87) NS   
Women 38 27 36 21 27 NS   
Clinical               
Systolic blood pressure (mmHg)* 131.5 (20.5) 132.2 (21.0) 125.0 (21.6) 121.7 (12.6) 123.1 (16.7) NS   
Diastolic blood pressure (mmHg)* 73.0 (9.2) 74.2 (10.1) 72.1 (10.3) 74.5 (7.3) 74.0 (8.9) NS   
Physical inactive (< 30 min/day) 23 (55) 16 (62) 16 (44) 9 (53) 31 (40) NS   
Ex-smokers 15 (36) 17 (65) 22 (61) 14 (74) 37 (47) NS   
Current smoking 13 (31) 6 (23) 7 (19) 5 (26) 28 (36) NS   
Body mass index (kg/m2)*               
                       Women 32.7 (6.9) 37.2 (7.4) 27.5 (4.7) 30.0 (8.3) 27.6 (4.6) < 0.005   
                       Men 29.86 (4.3) 29.1 (4.4) 27.5 (4.0) 29.8 (4.2) 26.5 (3.6) < 0.005   
Waist circumference (cm)*               
                       Women 107.3 (3.1) 110.7 (9.5) 91.3 (12.5) 104.8 (25.6) 94.3 (13.8) < 0.01   
                       Men 107.5 (11.7) 105.5 (10.8) 101.0 (12.4) 107.5 (10.4) 98.9 (11.0) < 0.01   
Ankle/brachial pressure index < 0.9 16 (38) 8 (31) 9 (25) 7 (37) 12 (15) NS   
Exercise capacity (Mets)* 5.53 (1.0) 5.68 (1.2) 6.40 (1.3) 5.73 (1.5) 6.73 (1.6) < 0.001   
Biochemical               
Total cholesterol (mmol/l)* 4.17 (1.1) 4.70 (1.3) 4.75 (1.3) 4.98 (1.3) 4.85 (1.0) < 0.05   
HDL-cholesterol (mmol/l)* 1.17 (0.4) 1.21 (0.3) 1.36 (0.5) 1.28 (0.4) 1.33 (0.3) NS   
LDL-cholesterol (mmol/l)* 2.17 (0.9) 2.57 (1.0) 2.74 (1.1) 2.88 (1.2) 2.89 (0.9) < 0.005   
VLDL-cholesterol (mmol/l)* 0.72 (0.4) 0.82 (0.39) 0.66 (0.3) 0.82 (0.4) 0.59 (0.3) < 0.01   
Triglycerides (mmol/l)* 1.83 (1.3) 1.81 (0.9) 1.47 (0.6) 1.80 (0.9) 1.48 (1.0) NS   
Fasting plasma glucose (mmol/l)* 8.20 (2.3) 7.76 (1.1) 5.64 (0.7) 6.24 (0.4) 5.34 (0.5) < 0.0001   
HbA1C (%)* (range) 7.35 (5.1-11.0) 6.55 (5.0-7.8) 5.94 (5.1-6.9) 6.02 (5.2-6.8) 5.73 (5.0-6.7) < 0.0001   
Hyperinsulinemia (>51 pmol/L) 26 (62) 22 (85) 18 (50) 11 (58) 25 (32) < 0.0001   
HOMA-IR* 5.73 (6.6) 4.67 (1.6) 2.34 (1.5) 2.85 (1.1) 1.83 (1.2) < 0.0001   
Fasting plasma C-peptide (pmol/l)* 1069.4 (513.7) 1256.6 (438.2) 1017.0 (490.9) 1031.3 (322.0) 837.2 (426.8) < 0.05   
Microalbuminuria (2,5-25 mg/mmol)* 11 (26) 3 (12) 3 (8) 2 (11) 6 (8) < 0.05   
Macroalbuminuria (>25 mg/mmol)* 7 (17) 0 0 1 (5) 0 < 0.0001   
* Mean (SD). Data are number (%) unless otherwise indicated.  ** p values are for the difference between the groups.    
NGT, patients with no glucometabolic abnormality according to the WHO definition; IFG, Impaired fasting glucose according to the  
WHO definition; IGT, Impaired glucose tolerance; ST2DM, Screen-detected type 2 diabetes; KT2DM, known type 2 diabetes at  
baseline.        
 
5.2. Prevalence of IGM in the DANSUK study 
Besides the 42 patients (42/201, 21%; 95% CI:15%;27%) who had KT2DM, 26 patients (26/201, 13%; 
95% CI:8%;18%) had screen detected type 2 diabetes (ST2DM), 36 patients (36/201, 18%; 95% 
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CI:13%;23%) had IGT and 19 patients (19/201, 9%; 95% CI:5%;13%) had isolated IFG. Thus 123 pa-
tients of the patients in the DANSUK study had glucose intolerance (123/201, 61%, 95% CI:54%;68%) 
according to the WHO definitions (table 4.2). Overall 38% (26/68, 95% CI:29%;47%) of the patients 
with T2DM had ST2DM. 
 
5.3. Age-and sex specific prevalence of IGM 
In the DANSUK study, significantly more patients above the age of 50 years had IGM (65%, 95% 
CI:58%; 72%) compared to the patients below 50 years (32%, 95% CI:14%; 50%) (p<0.009) and in the 
middle-aged group more than 15% (95% CI:9%;21%) of the patients had ST2DM. Only the prevalence 
of IFG varied between the three age groups (p<0.002). There was no statistically significant difference in 
the prevalence of IGM between women and men. Nearly 67% (95% CI:55%; 79%) of the women and 
59% (95% CI:51%; 67%) of the men had IGM. 
 
 
5.4. IGM and cardiac disease group assignment 
There was no statistical significant difference in the prevalence of IGM between the three groups in the 
DANSUK study (figure 5.2). Within the group of IHD, IGT was significantly more prevalent than T2DM 
and IFG (p<0.02). 
 
5.5. The WHO definition compared to the ADA criteria 
Using the ADA criteria (table 4.2), 36% (73/201) of the DANSUK population would be characterized as 
IFG thus increasing the prevalence by 100% compared to the 18% (36/201) according to the WHO defi-
nition. But the IFG category according to the ADA criteria would contain 19% (5/26) of the patients with 
ST2DM and fasting normoglycaemia and 37% (29/78) of the patients diagnosed as NGT according to the 
WHO definition (figure 5.3). Likewise 44% of the patients with IGT would be characterized as having 
NGT. 
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Figure 5.1. Sex- and age specific prevalence of IGM in the DANSUK study 
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In the DANSUK study all the patients with fasting normoglycaemic ST2DM had plasma glucose levels 
between 6.1-6.9 mmol/l and therefore would had been detected if an OGTT was performed in patients 
with IFG [69] (table 5.3). 
 
 
  
 
5.6. FPG as a screening tool 
In clinical practice, IFG is much easier to diagnose than IGT so in the efforts of trying to limit the need 
for OGTTs, it is interesting to determine how efficient the condition of IFG is to predict IGT according to 
both the WHO and the ADA definitions. Table 5.3 illustrates the concordance rate between the OGTT and 
FPG-values in diagnosing IGM both according to the WHO definition and the ADA criteria. The majority of 
the patients diagnosed with NGT had a referral value of FPG below 7.0 mmol/l. Thus it is reasonable to 
believe that the patients in the DANSUK study were truly fasting. 
 Figure 5.3. Metabolic group assignment in the DANSUK study according to the WHO definition and the ADA criteria.     
*compared to the WHO definition 
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Figure 5.2. Prevalence of IGM according to cardiac disease group 
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The sensitivity of a screening test is the proportion of diseased individuals who test positive on the 
screening test. The specificity is the proportions of non-diseased individuals who test negative on a 
screening test. The predictive values refer to the probability of being non-diseased given a negative test 
(PV-) or the probability of being diseased given a positive test (PV+). The predictive values rely on the 
prevalence of the disease seen in the population. This is part of the rationale for targeted screening in 
high-risk populations. Table 5.4 shows the evaluation of test performance when using IFG in predicting 
T2DM or IGT. Increasing the sensitivity of a test, by lowering the cut-off for positivity, as in the latest 
ADA criteria, results in a classical example of diminishing test specificity. And even more important is the 
hereby lack of improvement of the negative predictive value, which is unchanged as well as an 
inappropriate decrease of the positive predictive value. 
 
  
  Sensitivity Specificity PV- PV+ 
WHO 61 (38/62) 80 (78/97)   76 (78/102) 67 (38/57) 
         
ADA 74 (46/62) 51 (49/97) 75 (49/65) 49 (46/94) 
    
     
 
 
 
The classification in table 5.3 and 5.4 is based upon two consequtively taken FPG-values. Lowering the 
FPG-level according to the ADA criteria only improves the sensitivity by 21%, but the specificity drops by 
one-third and the negative predictive value remains unchanged (table 5.4). If the metabolic classification 
were to be based upon a single FPG-value, the classification would have another appearance (table 5.5). 
To simplify the process of screening in the settings of CR, another approach could have been to combine 
single values of FPG and HbA1c at referral also seen in table 5.5. Classifying the patients only using a 
single FPG-value result in an immediate overestimation of IGM. By the performance of an OGTT only in 
Table 5.3. Distribution and concordance of the exact number of glucometabolic abnormalities in the 
DANSUK study according to the diagnostic criteria defined by the WHO and the ADA (WHO/ADA). The 
final metabolic classification was based on the outcome of the OGTT and on two independently taken 
FPG values.  Bolded numbers denotes the patients overlooked or misclassified if an OGTT is omitted. 
 
Table 5.4. Evaluation of IFG according to the WHO definition and ADA criteria in predicting IGM (T2DM 
or IGT) in the DANSUK study.  PV-, negative predictive value; PV+, positive predictive value. Numbers 
taken from table 5.3. 
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the patients that could be classified as metabolic uncertain (FPG-values between 5.6 mmol/l to 6.9 
mmol/l), more than half of the OGTTs could be omitted at the expense of 44% (16/36) of the patients 
with IGT being misclassified as having NGT. If the WHO definition is used in the same way, 75% of the 
OGTTs could have been spared overlooking 67% (24/36) of the patients with IGT. 
 
Table 5.5. Evaluation of using IFG defined by a single FPG-value according to the  
WHO and the ADA criteria alone or in combination with an HbA1c-value in the proces 
of screening for IGM (T2DM or IGT) in the DANSUK study 
      
Screening criteria Sensibility Specificity PV- PV+  
IFG(WHO) (single FPG-value) 41 94 60 87  
  (33/33+48) (73/73+5) (73/73+48) (33/33+5)   
IFG(ADA) (single FPG-value) 53 63 56 60  
  (43/43+38) (49/49+29) (49/49+38) (43/43+29)   
IFG(WHO) + HbA1c>6.4% 9 99 51 88   
  (7/7+74) (77/77+1) (77/77+74) (7/7+1)   
IFG(ADA) + HbA1c>6.4% 9 95 50 64   
  (7/7+74) (74/74+4) (74/74+74) (7/7+4)   
Values are percentage. Absolute number of patients in brackets.   
PV-, negative predictive value; PV+, positive predictive value; FPG, fasting plasma glucose 
  
      
The sensitivity of all the screening proposals in table 5.5 is considered low for a high-risk population. 
While there is no improvement in the predictive value of a negative test (PV-), the specificity is relatively 
high. The sensitivity is increased by 29% when using a single FPG-value according to the ADA criteria 
compared to the WHO definition with no improvement in predictive values or specificity. The attribution 
of the HbA1c to a single FPG-value in the screening process seems useless in the DANSUK population. 
 
5.7. Cardiovascular risk profile 
The baseline cardiovascular risk profile of the patients additionally diagnosed with IFG according to the 
ADA criteria (FPG between 5.6 mmol/l and 6.0 mmol/l) differed significantly in insulin resistance, HbA1c 
and BMI which were all worse compared to the patients diagnosed with NGT (FPG<5.6 mmol/l) according 
to the same criteria (all p<0.02). The additionally diagnosed IFG patients were also less insulin resistant 
and had fewer signs of PAD and a better exercise capacity compared to the patients with FPG values 
between 6.1 mmol/l and 6.9 mmol/l (all p<0.05). The patients with IGT and IFG according to both the 
WHO and the ADA criteria were more insulin resistant, more obese and had suffered more myocardial 
infarctions than the patients with IGT and normal FPG values (all p<0.03) who again had a worse risk 
profile compared to the patients with NGT (all p<0.05). The patients with ST2DM had significantly lower 
HbA1c, higher plasma insulin levels, and they had suffered fewer myocardial infarctions compared to the 
patients with KT2DM (all p<0.05). 
 
5.8. Predictors of IGT and T2DM 
In a univariate analysis, nearly all the baseline variables inserted (age, gender, arterial hypertension, 
dyslipidemia, waist circumference, BMI>25 kg/m2, FPG>6.9 mmol/l, HbA1c>6.4%, ABPI<0.9, hyperinsu-
linemia, microalbuminuria, HOMA-IR>1.76) were predictors of T2DM. Haemoglobin A1c above 6.4%, FPG 
above 5.5 mmol/l and waist circumference were predictive of IGT. In model 1 where the possible 
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mediators of glucose intolerance were allowed to enter, FPG and HbA1c stayed as the only and strongest 
predictors of IGT and T2DM. In model 2 where all the possible mediators were withdrawn, only arterial 
hypertension remained an independent predictor of IGT (OR: 2.9, 95% CI: 1.1-5.9, p<0.05). In model 2, 
age (OR: 1.1, 95% CI: 1.0-1.2, p<0.05), BMI above 25 kg/m2 (OR: 1.22, 95% CI: 1.1-1.3, p<0.0001), 
arterial hypertension (OR: 2.9, 95% CI: 1.1-6.3, p<0.01) and low exercise capacity (OR: 0.6, 95% CI: 
0.4-0.8, p<0.0001) emerged as strong independent predictors of T2DM. Unfortunately the collection of 
data on family history of diabetes was incomplete and could not be used in the analysis of variance. 
 
5.9. Discussion 
The DANSUK study has shown that the prevalence of IGM in a broad group of patients eligible for CR is 
high. More than 40% of the patients had a previously unrecognized glucometabolic abnormality according 
to the WHO definition. The prevalence of the different metabolic groups in the IHD group in the DANSUK 
study is in accordance with the elective group in the European Heart Survey. In the DANSUK study there 
were fewer patients with KT2DM and more patients with isolated IFG reflecting a less diseased population 
[27]. The prevalence of glucose intolerance in patients with CHF is known to be high [288-290] but this 
was not the case in the DANSUK study most obvious due to a small sample size since only 16 patients 
(8%) were stratified to the CHF group. 
The proportion of ST2DM was relatively high especially in the middle-aged group and 
among men (figure 5.1), which coincide with the findings in the Inter99 study [61]. The high ratio 
between ST2DM and KT2DM in the DANSUK study was surprising when taking into account that the 
patients had just been discharged from a department specialized in cardiology undergoing intensive 
observation for CVD. On the other hand, selection bias could have occurred due to selective non-
participation of individuals with long-standing KT2DM with severe co-morbidities (mean duration of 
KT2DM in non-participants was not registered). Most likely it reflects selective overrepresentation of 
overweight and obese patients in the DANSUK study. It is note worthy that the mean BMI in the patients 
with KT2DM was 33 kg/m2 at baseline in the DANSUK study (table 5.1). Comparing this to the BMI values 
shown for the different populations in table 2.1, it is obvious that CR programmes draw the attentions 
from the most obese. Thus the high ratio between ST2DM and KT2DM reflects the continued screening 
potential for T2DM in departments of cardiology and that it should be done also in the younger patients. 
The crude prevalence of ST2DM in the DANSUK study is less than in other studies of patients with CVD 
[87,88], which is partly explained again by the heterogeneity of the DANSUK population including 30% 
high-risk individuals. This could also explain the relatively high concordance rate of IGT and IFG between 
the DANSUK study and the Inter99 population [61]. In the Inter99 study the crude prevalence of IGT 
among the patients in the sixties was 17.5%, and nearly 34% of the women and 50% of the men had 
glucose intolerance by the age of 60 [61]. 
 Even if one-third of the patients diagnosed with NGT according to the WHO definition, had 
hyperinsulinaemia at baseline (table 5.2) they were in general less obese, had lower blood pressure, 
lower levels of VLDL-cholesterol and fewer signs of PAD. There was also a considerable difference in the 
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baseline exercise capacity and in the level of insulin resistance between the patients with NGT and the 
patients with glucose intolerance. The exercise capacity seemed inverse proportional to the insulin 
resistance. The patients with ST2DM and KT2DM had very high levels of insulin resistance compared to 
both the patients with prediabetes and the patients with NGT but at least part of this difference could be 
due to the use of insulin in the patients with KT2DM making the HOMA-IR less reliable in this population. 
The difference in cardiovascular risk profile between the patients with isolated IFG and IGT deserves 
some comments. Impaired glucose tolerance and IFG represent two different stages in the glucose 
continuum without them necessary preceeding each other or T2DM. Impaired glucose tolerance is still 
considered more hazardous with regard to the development of CVD and T2DM. Although the group was 
relatively small (N=19) the patients with isolated IFG in the DANSUK study exhibited a worse cardiovas-
cular risk profile than the patients with IGT. These findings both disagree and coincide with the findings 
in different population-based studies [291,292]. The patients with isolated IFG had a more sedentary life 
style, they were more obese and insulin resistant and had as low exercise capacity as the patients with 
ST2DM and the same high prevalence of PAD. A sample of cardiovascular risk factors that make them 
very suitable for CR even though there is no evidens from randomized controlled trials that they benefit 
the same as patients with IGT. Thus in the DANSUK study, the cardiovascular risk profile associated with 
IFG defined by both definitions was statistically different from that associated with isolated IGT and NGT. 
This may justifie the use of the ADA criteria of IFG as an independent category of the glucose homeo-
stasis although obviously not suitable as a screening tool for IGT. Many of the patients with IGT had 
normal FPG values and the majority were still normoglycaemic when repeating the tests (89%) 
emphazising the continued need of the OGTT regardless of FPG-values.  
Unlike the DECODE study [62], IFG was efficient in predicting T2DM in the DANSUK study 
since all the patients with ST2DM were classified as IFG. No other risk factors or symptoms were 
conspicuous and would single them out from the rest of the patients diagnosed with IFG. Only an OGTT 
would finally reveil the diagnosis and would induce the patients to enter a surveillance programme for 
retinopathy and nephropathy much less cause referral to a patient education programme. Using HbA1c as 
a screening tool is questionable. The cut-off value of the used HbA1c in the DANSUK study is relatively 
high and caused a low sensitivity and low positive predictive value when used alone as a screening tool. 
Nothing was gained by ascribing HbA1c to a single FPG-value in the process of screening and metabolic 
classification upon a single FPG-value overestimated the prevalence of IGM in the DANSUK study.  
 
5.10. Conclusions (DANSUK 1)    
 
• More than 60% of the patients in the DANSUK study had impaired glucose metabolism and 38% 
of the patients with type 2 diabetes had screen detected type 2 diabetes. 
 
• Omitting the oral glucose tolerance test, 19% of the patients with screen detected type 2 
diabetes would have been misclassified as impaired fasting glucose. 
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• The prevalence of impaired glucose tolerance was high emphasizing the great potentials in 
preventing type 2 diabetes in the settings of cardiac rehabilitation. 
 
• Concordance rate between the WHO and the ADA criteria was low in the DANSUK study. 
 
• Cardiovascular risk profile in means of metabolic parameters and body mass index was worse in 
the patients additionally diagnosed with impaired fasting glucose according to the ADA criteria 
compared to the patients who remained normal glucose tolerant. 
 
• In the DANSUK study known arterial hypertension at baseline was a predictor of impaired glucose 
tolerance and age, a body mass index above 25 kg/m2, arterial hypertension and a low physical 
exercise capacity were independent predictors of type 2 diabetes. 
 
• If not performed at referral to the unit of cardiac rehabilitation, an oral glucose tolerance test 
should be performed to establish a proper risk factor profile considering both cardiovascular and 
diabetic risk factors with the possibility of adjusting actions of behavioural interventions and 
treatment goals. 
 
• A combined stepwise screening method using impaired fasting glucose according to the ADA 
criteria and HbA1c to limit the need of an oral glucose tolerance test was inefficient in classifying 
patients with impaired glucose tolerance. 
 
• The prevalence of impaired glucose metabolism is overestimated in the DANSUK population if 
single fasting plasma glucose values are used.  
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Part IV: Intensive multifactorial intervention towards patients with IGM 
6. Results – DANSUK 2 (Article 2, appendix 4) 
6.1. Baseline characteristics of the two study groups 
Of the patients included in the DANSUK study, 53 patients (52%) randomized to UC had T2DM 
(KT2DM=20; ST2DM=14) or IGT (19 patients) and 51 patients (52%) randomized to CR had T2DM 
(KT2DM= 22; ST2DM=12) or IGT (17 patients). Table 6.1 depicts the demographic and clinical 
characteristics upon entry into the study in the patients with IGM (T2DM or IGT). 
Table 6.1. Patients characteristics of the DANSUK study (N = 104)  
    
  Usual care  
Cardiac 
rehabilitation   
  (N = 53) (N = 51)   
Demographic       
Age (years/range) 65.5 (42-89) 62.3 (43-81)   
Women 36 33   
Stratification       
Congestive heart disease 3 (6) 4 (8)   
Ischemic Heart Disease 35 (66) 35 (69)   
High-Risk patients 15 (28) 12 (23)   
Previous history       
Myocardial Infarction 10 (19) 11 (22)   
Revascularization 28 (53) 24 (47)   
Known systemic hypertension 39 (74) 35 (69)   
Known hypercholesterolemia 45 (85) 37 (73)   
Clinical       
Ambulatory systolic bloodpressure (mmHg) 129.5 (21.9) 129.3 (20.3)   
Ambulatory diastolic bloodpressure (mmHg) 71.1 (9.4) 74.2 (10.1)   
Physical inactive (< 4 h/week) 21 (40) 28 (55)   
Body mass index (kg/m2)       
     Women 31.7 (6.5) 31.8 (7.6)   
     Men 28.8 (3.9) 28.8 (4.6)   
Waist circumference (cm)       
     Women 102.4 (14.1) 101.9 (15.5)   
     Men 103.9 (12.7) 105.6 (11.1)   
Ancle-Brachial Pressure Index < 0.9 22 (42) 11 (22)   
Metabolic equivalents 5.9 (1.2) 5.9 (1.3)   
Biochemical       
Total cholesterole (mmol/l) 4.60 (1.3) 4.43 (1.1)   
HDL cholesterole (mmol/l) 1.25 (0.3) 1.24 (0.5)   
LDL cholesterole (mmol/l) 2.56 (1.1) 2.37 (0.9)   
VLDL cholesterole (mmol/l) 0.69 (0.4) 0.76 (0.3)   
Triglycerides (mmol/l) 1.69 (1.2) 1.71 (0.8)   
Fasting plasma glucose (mmol/l) 8.20 (2.1) 5.91 (1.1)   
HbA1C (%) 7.35 (1.3) 5.95 (0.6)   
Hyperinsulinemia (≥ 51 pmol/L) 26 (62) 76 (48)   
Microalbuminuria (2,5-25 mg/mmol) 11 (26) 14 (9)   
Cardiovascular medication       
Aspirin 29 (69) 120 (75)   
ACEI/ARA 20 (47) 59 (37)   
β-blockers 19 (45) 78 (62)   
Statins 31 (74) 99 (62)   
Mean values or exact numbers. Brackets are 1 SD or %. ACEI, angiotensin-converting  
Inhibitor; ARA, angiotensin receptor-II antagonist  
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The randomization was well balanced with no statistical difference at baseline between the two 
intervention groups. At baseline there was also no significant difference between the two treatment 
groups in the use of oral hypoglycaemic agents or insulin. Overall the population was a fairly well treated 
group of mostly ischemic obese patients half of them with a history of revascularization. 
 
6.2. Main results 
The main results of the multifactorial intervention on clinical, biochemical, and behavioural outcome in 
the CR compared to UC are shown in table 6.2 and in table 6.4. The patients with IGM in the CR group 
obtained a significantly greater mean change in HbA1c, FPG, insulin resistance, systolic and diastolic blo-
od pressure compared to usual care. The exercise capacity also improved significantly in the patients with 
IGM. 
 
Table 6.2.  Changes at the end of the study in clinical, biochemical and behavioural variables    
                   
  Impaired glucose metabolism Normal glucose tolerance   
               
  IGT/UC IGT/CR T2DM/UC T2DM/CR IGM/UC IGM/CR UC CR   
  (N=18) (N=17) (N=29) (N=32) (N=47) (N=49) (N=47) (N=44)   
Clinical                   
Systolic blood pressure (mmHg)* -1.33 (24.3) -1.68 (14.9)
¥
 -0.80 (15.6) -8.40 (15.3)
†
 -0.09 (19.5) -6.04 (15.3)
†
 0.43 (10.7) -0.34 (14.0)
¥
   
Diastolic blood pressure (mmHg) * 0.94 (10.7) -1.88 (7.7)
¥
 -0.20 (6.7) -4.87 (8.7)
†
 0.28 (8.5) -3.83 (8.4)
†
 -0.70 (11.5) 0.24 (8.4)   
Body mass index (kg/m2)* 0.85 (1.6)
†
 0.07 (1.3) -0.09 (1.8) -0.18 (1.7) 0.27 (1.8) -0.11 (1.6) 0.43 (2.0) -0.04 (1.7)   
Waist circumference (cm)* -1.67 (7.8) -0.17 (4.7) -3.13 (5.2)
†
 -3.72 (6.9)
†
 -2.55 (6.3)
†
 -2.45 (6.5)
†
 -0.61 (6.2) -3.22 (6.1)
†
   
Weight changes (kilo pounds)* 2.5 (4.8)
†
 0.20 (3.5) -0.18 (5.1) -0.36 (4.9) 0.88 (5.1) 0.17 (4.5) 1.4 (5.8) -0.03 (5.4)   
Weight (mean in kilo pounds)** 76.6/79.2 79.1/79.3 87.4/89.2 89.6/89.6 83.5/85.3 86.1/86.0 79.7/81.0 86.3/86.1   
Current smokers** 2/2 5/4 9/9 10/8 11/11 15/12 18/15 15/14   
Exercise < 30 min/day**   10/10 6/3 22/17 17/11 32/27 23/14
†
 15/15 25/10
†
   
Exercise capacity (Mets)* -0.48 (0.6)
†
 0.06 (0.8) 0.07 (0.8) 0.31 (0.8)
¥
 -0.18 (0.8) 0.21 (0.8)
†
 -0.17 (1.1) 0.39 (0.8)
†
   
HOMA-IR 1.52 (4.8) 0.26 (1.3) 0.62 (4.1) -0.52 (2.9)
†
 0.97 (4.3)
†
 -0.26 (2.5)
†
 0.04 (1.1) 0.26 (1.8)   
Biochemical                   
HbA1C* -0.02 (0.3) 0.01 (0.4) -0.08 (0.7) -0.65 (0.9)
†
 -0.06 (0.6) -0.42 (0.8)
†
 -0.10 (0.4) -0.14 (0.4)   
Fasting plasmaglucose (mmol/l)* 0.54 (0.6)
†
 0.09 (0.5) 0.38 (2.1) -0.97 (2.2)
†
 -0.01 (1.9) -0.60 (1.8)
†
 -0.03 (0.7) -0.15 (1.0)   
Total cholesterol (mmol/l)* -0.12 (0.7) -0.26 (1.0)
†
 0.16 (1.0) -0.13 (0.8)
¥
 0.04 (0.9) -0.18 (0.9) 0.03 (0.8) -0.25 (1.1)
†
   
HDL cholesterol (mmol/l)* 0.24 (0.3)
†
 0.19 (0.3)
†
 0.19 (0.3)
†
 0.21 (0.2)
†
 0.21 (0.3)
†
 0.20 (0.2)
†
 0.16 (0.2)
†
 0.22 (0.2)
†
   
LDL cholesterol (mmol/l)* -0.44 (0.7)
†
 -0.62 (1.0)
†
 -0.08 (0.7) -0.22 (0.7)
¥
 -0.24 (0.7)
†
 -0.37 (0.8)
†
 -0.21 (0.7)
†
 -0.47 (1.0)
†
   
Triglycerides (mmol/l)* 0.14 (0.7) 0.28 (0.7) 0.18 (1.0) 0.03 (0.7) 0.16 (0.8) 0.12 (0.7) 0.20 (0.8) -0.04 (0.9)   
Impaired glucose metabolism (IGM) denotes type 2 diabetes (T2DM) and impaired glucose tolerance (IGT); UC, Usual care; CR, Cardiac rehabilitation  
One Mets, resting metabolic rate at 3.5 ml O2/kg/min; *Plus-minus values are means ± SD;  ** at baseline and at the end of the study; bolded values  
denotes p<0.05 versus usual care;
 †
 p<0.05 versus baseline; 
¥
 p<0.06 versus baseline and usual care 
 
  
In spite of the lack of standardized questionnaires concerning hypoglycaeminc events in the DANSUK 
study, only a few reported having experienced light to moderate symptoms of hypoglycaemia (1 patient 
in the CR group and 2 patients in UC group). No significant difference from usual care was obtained in 
total-, LDL-, HDL- cholesterol or triglycerides, BMI, waist circumference, total body weight or in the 
number of ex-smokers. The patients with T2DM had the greatest improvements in glycaemic parameters, 
blood pressure, LDL- and VLDL-cholesterol. The HbA1c decreased more than 9% during the study period 
compared to a decrease of little more than 1% in the usual care group (table 6.4). 
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Table 6.3 shows where the treatment and follow-up visits of the patients in the usual care group took 
place during the study. In the following the difference in the primary and secondary endpoint will be 
discussed in details. Data of the effect of CR in patients with IGT is very limited, so many of the 
comparisons to other trials will mainly concern the patients with T2DM. 
 
     
 Table 6.3. Follow-up during study period in the usual care group  
     
   Diabetes care
* Cardiac care  
 General practitioner 56% 15%  
 Specialized department 44% 85%  
 38% of the patients had 1-2 visits at the outpatients clinic before referral to the  
 general practitioner; Diabetes care, department of endocrinology at Bispebjerg  
 University Hospital or Steno Diabetes Center; Cardiac care, department of  
 cardiology at Bispebjerg University Hospital; 
*only patients with T2DM  
     
 
6.3. Discussion 
6.3.1. Intensive treatment of hyperglycaemia (primary endpoint) 
The mean change of HbA1c in the patients with IGM randomized to CR was significantly greater than the 
mean change obtained in the UC group (table 6.2). The decline in the HbA1c was even greater in the 
patients with T2DM and most pronounced in the patients with KT2DM attending CR (figure 6.1).  
 
 
 
 
The patients and the caretakers in the UC group had access to the test results and the patients in the UC 
group also received written information of the result of the OGTT and how to react if they had been 
diagnosed with glucose intolerance (the patients were advised to contact their physician). The OGTT was 
performed 3 months after inclusion. Hereafter the HbA1c declines in both treatment groups in the 
patients with ST2DM, reflecting patients and caretakers action upon the new knowledge. It is highly 
possible that the decline of the HbA1c in the UC group would have failed to appear, if the test result had 
not been accessible. In the CR group the mean HbA1c in the patients with ST2DM starts to decline before 
Figure 6.1. Changes over time in HbA1c in patients with KT2DM and ST2DM 
in both treatment groups (UC: N = 34/29; CR: N = 34/32) 
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the metabolic diagnosis was known (figure 6.1). This could reflect the ‘pure’ effect of comprehensive CR 
upon glycaemic control, although the decline was not statistically different from the change in the UC 
group (p=0.16). In all patients with T2DM, the mean decline of HbA1c after 3 months of follow-up in the 
CR group was significantly different from the UC group (p=0.02). Being an open randomised study 
physicians in the UC group knew that their therapy and efforts would be compared with a more intensive 
treatment. This could have influenzed the initial although limited decline in the HbA1c in the patients with 
KT2DM in the UC group. As time went by, the results from the obligatory assessments visits in the UC 
group stopped followed by deterioration in HbA1c (figure 6.1). 
The mean decline in HbA1c of -0.65 % (9% improvement) in the patients with T2DM in 
the CR group after one year is comparable with the results obtained in the STENO 2 study (study 
duration: 7.8 years; mean HbA1c decline: -0.5%; percentage improvement: 13%) [105], the DIGAMI I 
(study duration: one year; mean HbA1c decline: -0.3%; percentage improvement: 4%) [156] and the 
DIGAMI II study (study duration: two years; mean HbA1c decline: 0.5%; percentage improvement: 7%) 
[161] (table 2.4). In the STENO 2 study, the greatest decline in HbA1c appeared within the first year of 
intensive treatment. In the following years and until the end of the study, HbA1c stabilized itself around a 
mean of 7.6% [105]. The relatively impressive decline in HbA1c with 0.9% (13% improvement) in the 
UKPDS was only maintained for a short period. During the following 9 years the HbA1c increased to a 
mean of 8%. 
 
Table 6.4. Mean values of different risk factors at baseline, after 12 months of follow-up, and as percentage 
change of baseline values in the patients with T2DM in the two study groups 
   
  Usual care Cardiac rehabilitation  
  Baseline Follow-up % change Baseline Follow-up % change   
  (N = 34) (N = 29) from baseline (N = 34)  (N = 32) from baseline   
Clinical               
Systolic blood pressure (mmHg) 131 (21) 129 (23) -1.4 132 (21) 125 (16) -5.4
†
   
Diastolic blood pressure (mmHg) 72 (9) 71 (11) -0.7 75 (10) 70 (7) -7.3
†
   
Body mass index (kg/m2)               
     Women 34.8 (5.7) 36.8 (4.3) 5,6 33.4 (8.0) 32.6 (8.3) -2.4   
     Men 29.4 (4.8) 29.4 (6.0) 0 29.5 (3.8) 29.7 (4.1) 0.7   
Body weight (kg)               
     Women 87.4 (14.8) 92.6 (12.0) 6.0 88.0 (23.2) 85.8 (23.9) -2.5   
     Men 87.4 (17.5) 87.6 (21.4) 0.2 90.4 (11.1) 91.5 (12.5) 1.2   
Waist circumference (cm)               
     Women 110.2 (9.8) 109.1 (8.8) -1.0
†
 106.3 (14.2) 101.9 (16.0) -3.9
†
   
     Men 105.3 (12.0) 103.1 (15.4) -2.1
†
 108.0 (10.6) 105.1 (10.9) -2.7
†
   
Exercise capacity (Mets) 5.6 (1.2) 5.6 (1.6) 0 5.7 (1.0) 5.9 (1.1) 3.5   
Biochemical               
Total cholesterol (mmol/l) 4.4 (1.4) 4.5 (1.2) 2.3 4.4 (1.0) 4.3 (0.7) -2.3   
HDL cholesterol (mmol/l) 1.2 (0.3) 1.3 (0.4) 8.3
†
 1.2 (0.4) 1.4 (0.4) 16.7
†
   
LDL cholesterol (mmol/l) 2.3 (1.1) 2.2 (1.0) -4.5 2.3 (0.9) 2.1 (0.5) -8.7   
VLDL cholesterol (mmol/l) 0.7 (0.4) 0.8 (0.3) 14.3 0.8 (0.4) 0.7 (0.3) -12.5   
Triglyceride (mmol/l) 1.9 (1.3) 2.2 (1.3) 15.8 1.8 (1.0) 1.8 (1.2) 0   
Fasting plasma glucose (mmol/l) 7.9 (1.6) 8.2 (2.1) 3.8 8.2 (2.2) 7.3 (1.8) -11.0
†
   
HbA1C (%) 6.95 (1.1) 6.87 (1.2) -1.2 7.13 (1.2) 6.48 (0.8) -9.1
†
   
Brackets are 1 SD. Bolded values denotes p<0.05 versus usual care. 
†
 p<0.05 versus baseline 
One Mets, resting metabolic rate at 3.5 ml O2/kg/min 
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There are very limited data on the effect of CR in patients with T2DM. The few existing studies are not 
randomized [26,55,56] and the information of any change in glycaemic control is often not available 
[55,56]. In one study of comprehensive CR including both patients with T2DM and patients with NGT, the 
only significant improvement obtained in the diabetic population, was in exercise capacity while the 
HbA1c increased 3% although not significantly [25]. 
 
6.3.2. Intensive treatment of blood pressure and lipids (secondary endpoints) 
Nearly 75% of the patients with IGM in the DANSUK study were registered as having arterial hyperten-
sion at baseline or as having had two measurements equal to or above 140/90 mmHg during admission 
(table 6.1). Looking at the 24-hour blood pressure measurement done at baseline in the patients with 
T2DM, 53% of the patients had a blood pressure equal to or above the intended treatment goal of 
130/80 mmHg. The decline of the systolic blood pressure in the patients with IGM randomized to CR was 
significantly greater than the decline obtained in the usual care group (table 6.2). The decline of the 
systolic blood pressure was greatest in the patients with T2DM as seen in figure 6.2 and in table 6.4. 
 
 
 
 
A mean decline of the systolic blood pressure of 8.4 mmHg in the T2DM patients in the CR group is 
remarkable. The measurements were done as 24-hour measurements considered being a more valid 
method than means of single sphygmomanometer measurements. The decline in the diastolic blood 
pressure was also significantly greater in the CR group compared to the UC group (mean difference: -4.9 
mmHg versus –0.2 mmHg, p<0.05) in the T2DM patients. Although measured in the supine position, it is 
difficult to compare mean blood pressure changes in the STENO 2 study to the mean changes obtained in 
the DANSUK study because measurements were performed with different methods. The mean change in 
the systolic blood pressure within the first year of the STENO 2 study in the intensively treated group was 
close to 8.0 mmHg. During the rest of the study period (mean 7.8 years) the systolic blood pressure kept 
on declining reaching a mean decline of 14.0 mmHg [105]. 
Figure 6.2. Changes over time in systolic blood pressure in patients with 
T2DM (K2DM + ST2DM) in both treatment groups (UC = 34/29; CR = 34/32) 
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When comparing the follow-up blood pressure in the patients with T2DM in the DANSUK with the follow-
up measurements in the studies shown in table 2.5, none of these studies obtained a mean blood 
pressure below 130/80 mmHg. Although the baseline values are considerable higher than in the DANSUK 
study, improvements of 4-8% in the systolic blood pressure resulted in a relative risk reduction in major 
cardiovascular events of 30-50% [202,199]. In the HOT study, small differences in follow-up blood 
pressures of 3-4% (144/85 mmHg vs 140/81 mmHg) in the patients with T2DM diminished the relative 
risk reduction for major cardiovascular events by one half [207] (table 2.5). The majority of the patients 
in the blood pressure-lowering trials shown in table 2.5 had no history of CVD. In the DANSUK study 
nearly half of the patients with T2DM had been revascularized and 15% had suffered an acute MI. Thus 
as they possess a higher absolute risk of cardiovascular events, a percentage improvement of 5% and 
7% in systolic and diastolic blood pressure most likely is beneficial. 
Although not significantly different from UC, all the lipids exept from triglyceride, showed 
an improvement from baseline of 2-17% with the improvement of LDL-cholesterol being nearly 9% (table 
6.4). In the trials shown in table 2.6, the percentage improvement of LDL-cholesterol using statins in the 
treatment of dyslipidaemia in patients with T2DM, varied from 20-35% with a mean baseline LDL-
cholesterol level of 3.55 mmol/l. These reductions in LDL-cholesterol induced a relative risk reduction of 
20-50% in major cardiovascular events. The improvements in total-, LDL-, and HDL-cholesterol in the 
DANSUK study coinside with the findings in other trials investigating the effect of comprehensive CR in 
patients with T2DM [25,55,56] (table 6.5). In the DANSUK study, both treatment groups had already at 
baseline a mean value of LDL-cholesterol (2.32 mmol/l) that had reached the predefined treatment goal 
(<2.50 mmol/l). A further lowering of 9% was possible although the size of the population was under-
powered to obtain significant differences. 
 
6.3.3. Intensive treatment of behavioral modifications (secondary endpoints) 
There was no significant change in BMI or total body weight within or between the two treatment groups 
in the DANSUK study. Waist circumference was significantly reduced during the study period among the 
patients with T2DM in both the CR and the UC group (table 6.3 and 6.4). It is remarkable that the 
patients in the CR group obtained an improved glycaemic control without gaining weight. But due to a 
small number of patients a significant improvement in BMI and total body weight compared to usual care 
may have been missed. Gaining weight is a common and inappropriate side effect when improving 
metabolic control and is often due to the increased use of hypoglycaemic drugs. In the UKPDS [168], the 
DCCT [171], the Kumamoto [170], and the STENO 2 study [104] the patients in the intensively treated 
groups gained weight. In the STENO 2 study the mean weight gain over the study period of 7.8 years 
was 3.7 kg in the intensively treated group compared to a mean weight gain of 0.5 kg in the control 
group (p=0.001). In the same study, the mean increase in hip circumference was 5 cm in the intensively 
treated group compared to a mean decline of 1 cm in the control group (p=0.048). Even if the intensively 
treated group in the Steno-2 study did not obtain a weightloss, they experienced a greater reduction in 
the ratio of daily intake of saturated and unsaturated fatty acids compared to the control group [104]. 
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Although not significantly different, all 4 metabolic group assignments in the CR group in the DANSUK 
study maintained their weight compared to a weight increase in all 4 groups in the UC group (table 6.2). 
One randomized controlled trial assessing the effect of a multifaceted intervention towards patients with 
T2DM in primary care also succeed in a metabolic improvement without the adverse weight gain [106]. 
In the patients with IGM, the CR group achieved a significant improvement of exercise ca-
pacity compared to a decrease in the UC group (p<0.05). There was also a significant difference in 
HOMA-IR between the 2 treatment groups (p<0.01)(table 6.2). Improving exercise capacity is beneficial 
in many aspects especially in patients with glucose intolerance. In the settings of CR, exercise training 
and individual physical guidance is one of the most established and substantial forms of treatment in 
patients with IHD. It improves both exercise capacity and the functional well being of the patients 
[114,293]. It also reduces re-hospitalizations and revascularizations [294]. After 1 year, the exercise 
capacity in the patients with T2DM in the CR group was almost significantly different from UC (p=0.067). 
Infact, the only group of patients receiving UC, who showed a trend towards an improvement in exercise 
capacity, were the patients with T2DM (table 6.2). It can only be speculated why the exercise capacity in 
the patients with T2DM in the CR group was only improved 3.5% compared to other trials obtaining an 
improvement of 26-38% [25,55,56]. The comprehensive CR programmes including the exercise program-
me are very similar in all three non-randomized studies but compared to the DANSUK study, they had a 
longer period of supervised exercise training (10-12 week) and a more intensive programme of three 
training lesions a week of 40-50 minuts. The most obvious reason for the difference between the above 
mentioned studies and the DANSUK study is, that the data from the DANSUK study is after 1 year of 
follow-up and not immidately after the intensive exercise period. In the Extensive Lifestyle Management 
Intervention study (ELMI) where 20% of the patients had T2DM, there was a non-significant im-
provement of 1.0% in exercise capacity in the overall population compared to UC where the exercise 
capacity decreased 1.0% in one year [295]. 
Of the 15 patients with IGM in the CR group that were smoking at baseline, 3 patients 
(20%) stopped smoking during the study period. None of the 11 patients with IGM in the UC group 
stopped smoking during the same period [table 6.2.]. A lack of difference could be due to the small num-
ber of patients in the DANSUK study. A greater study has shown that having suffered an acute MI and 
not attending a CR programme is an independent predictor of continued smoking (p=0.0008) [296]. A 
recent meta-analysis has also shown that CR creates more ex-smokers than usual care [31]. Thus, 
expectations of a higher smoking cessation rate than 20% during a comprehensive CR programme may 
be excessive [297]. In the randomized Extensive Lifestyle Management Intervention study (ELMI) in-
cluding 302 patients, no difference in the cessation rate between the UC group and CR group was found 
[295]. 
 
6.4. Obtaining treatment goals  
In the DANSUK study, there was a trend towards a higher degree of reaching the pre-defined treatment 
goals among the patients with T2DM in the CR group compared to UC (figure 6.3). The percentage of 
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patients in the intensively treated group in the STENO 2 study who obtained the treatment goal of HbA1c 
below 6.5% at the end of the study was 15% [105] compared to 66% in the CR group and 45% in the 
UC group in the DANSUK study. The percentage of patients with T2DM obtaining the other treatment 
goals was all close to the results of the STENO 2 study [105]. Obtaining a BMI below 25 kg/m2 was often 
more illustrative than realistic as it was never a goal by itself in the very obese. The lack of a weight loss 
in the patients with IGM may seem disappointing compared to the great effort that was put into the 
nutritional counselling. Obtaining an ideal metabolic control and healthier exercise behaviour may 
compensate for the lack of weight reduction. We may also argue, that the stable body weight could be 
due to a serious change of life style motivated by the supervised exercise training programme. This 
seems possible since there was no weight increase in any of the 4 metabolic groups in the CR group. 
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For some reason, achieving the pre-defined treatment goals in the patients diagnosed with IGT was a 
more difficult task than in the patients with T2DM (figure 6.4). At baseline this group later diagnosed with 
IGT seemed less metabolic deteriorated being the leanest of the 4 metabolic groups (mean BMI: 27.5 
kg/m2), less glycaemic deteriorated (mean HbA1c: 5.94%; mean FPG: 5.64 mmol/l) and having nearly as 
high a physical exercise capacity (mean mets: 6.40) as the patients diagnosed with NGT. The mean 
decline in systolic blood pressure in the IGT patients in the CR group almost reached statistical 
significance (p=0.057). In the CR group, the mean FPG value fell during treatment and physical capacity 
improved in the patients with IGT compared to UC. The mean decline in systolic blood pressure almost 
reached statistically significance in the patients with NGT in the CR group compared to UC (p=0.054). 
 
Figure 6.3.  Percentage of patients with T2DM who obtained the intensive predefined 
treatment goals in the CR group (N = 32) and in the UC group (N = 29). No statistical 
difference between treatment groups was obtained. 
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6.4.1. Pharmacological treatment 
After 12 months of follow-up the use of ASA, statin, ACEI/ARA, Ca-channel antagonists and diuretics had 
increased in the patients with T2DM in the CR group. The increased use of ACEI/ARA and Ca-channel 
antagonists was statistically different from the UC group (figure 6.5). Only a few patients with T2DM in 
the CR treatment group did not take ASA or statin at the end of the study due to intolerable side effects. 
The use of ACEI/ARA in the UC group also increased significantly during the study period. This was 
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mainly among the patients who were followed in the out patient clinic at the department of cardiology. At 
the end of study period, 88% of the patients with T2DM in the CR group had a daily intake of 2-4 blood 
pressure lowering medications compared to 71% in the UC group. 
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Figure 6.5. – Proportion of patients with T2DM using cardiovascular and hypoglycaemic drugs at baseline and at the end of 
study in the two intervention groups (CR: N = 34/32; UC: N=34/29).  
* p< 0.05 versus baseline; † p< 0.05 versus usual care 
*† 
*† 
* 
* 
* 
Figure 6.4. Percentage of patients with IGT who obtained the intensive pre-defined 
treatment goals in the CR group (N=17) and in the UC group (N=18). No statistical 
difference between treatment groups was obtained. 
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Corresponding numbers for patients with IGT was 59% in the CR group and 67% in the UC group. As 
seen in figure 6.5, many of the patients with T2DM were already being treated with ASA, ACEI/ARA and 
statins at baseline and the ones who were not, were mainly high-risk patients. In many of these patients 
the arguments for installing such a treatment was often obvious because of arterial hypertension, 
microalbuminuria or dyslipidemia. Mean intake of antihypertensive drugs by the patients with T2DM at 
baseline and at the end of study in the 2 study groups are shown in figure 6.6. 
Metformin was used to improve metabolic control in many of the patients because they 
were obese. It was well tolerated but because of the risk of the severe but rare lactic acidosis [298], the 
use of metformin was limited in the patients with CHF, although these patients seem to benefit when 
treated [299]. The use of ACEI/ARA, statin and ASA in the patients with IGT was not as intensive as in 
the patients with T2DM especially in the high-risk group. It was difficult in this group to overcome the 
barrier of starting a lifelong relatively expensive treatment with ACEI/ARA and statin in patients who 
neither were or felt themselves immediate cardiac or true metabolic diseased (figure 6.7). 
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6.4.2. Adherence to polypharmacy 
The patients in the DANSUK study were educated in the rationale for the prescribed polypharmacy. But it 
is well known that even when symptoms are present, start of new treatment may not always relieve 
these, and change of lifestyle can lead to improvements as well as reduction in quality of life, the latter 
being a potential barrier to adherence to medical therapy [300]. The successful polypharmacy obtained 
among the patients with T2DM in the DANSUK study were labour intensive and time consuming for the 
care providers. At times, it seemed difficult to comprehend that failure to achieve treatment goals could 
be related to inadequate self-management and often the pitfall was to intensify the pharmacological 
therapy to even more inconvenience for the patients. It was also very challenging to organize the therapy 
in high-risk symptom-less patients with multiple risk factors for CVD and newly diagnosed with T2DM. It 
often became a delicate balance between the threat of loosing a patient or creating a successful and self-
aware patient. 
Figure 6.6. Average number of antihypertensive agents (ACEI, ARA, β-blockers, ca-channel antagonists, 
diuretics) taken by the patients with T2DM at baseline (0) and at the end of the study (12) in the two study 
groups (UC: N = 34/29; CR: N = 34/32). No statistical difference was found. 
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6.5. Conclusions (DANSUK 2) 
• Compared to usual care, an intensified comprehensive cardiac rehabilitation with an integrated 
diabetes module is more efficient in improving glycaemic and blood pressure control, exercise 
capacity and insulin resistance in patients diagnosed with impaired glucose metabolism. 
 
• In patients with type 2 diabetes randomized to comprehensive cardiac rehabilitation, the value of 
HbA1c was brought below a level that has been shown to reduce diabetic complications. 
 
• In patients with type 2 diabetes randomized to comprehensive cardiac rehabilitation, the blood 
pressure was treated to below a level that has been shown to reduce both diabetic and 
cardiovascular complications. 
 
• Compared to usual care, improvement of metabolic control was obtained without weight increase 
and with no increase in hypoglycaemic events in the patients with type 2 diabetes randomized to 
cardiac rehabilitation. 
 
Figure 6.7. Proportion of patients with IGT using cardiovascular drugs at baseline 
and at the end of study. (CR: N=17; UC: N=18). No statistical difference between 
treatment groups was obtained. 
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7. Final comments 
New knowledge from the DANSUK study 
The DANSUK study has emphasized the need to identify patients with glucose intolerance in the settings 
of CR and target them for an aggressive program of multidisciplinary risk factor management, including 
exercise training. A correctly metabolic classification of these patients is important because of the 
possible difference in behavioural characteristics between patients with and without T2DM following 
major cardiovascular events. These behavioural differences may in fact contribute to the higher rate of 
future cardiovascular events. As in other studies, the patients with glucose intolerance had a worse 
cardiovascular risk profile at baseline than their metabolic normal counterparts. Thus from the beginning 
of the CR programme, patients with glucose intolerance have greater barriers to overcome to obtain the 
pre-defined treatment goals that are often more strict than the ones outlined for patients with NGT. 
By showing flaws in the metabolic classification by the use of FPG values alone, the 
DANSUK study have emphasized the necessity of screening all high-risk cardiac patients without a history 
of T2DM for glucose intolerance by the performance of an OGTT. 
The DANSUK study has reveiled that the patients additionally diagnosed with IFG by 
lowering the FPG threshold of NGT to 5.5 mmol/l did have a worse cardiovascular risk profile compared 
to the patients that remained normoglycaemic. Thus a new kind of glycaemic intolerant patients has 
evolved but whether the diagnosis will benefit them by participation in CR remains to be seen. Besides 
having an awareness of the IFG-condition, it is difficult to assign further initiatives than usual general risk 
factor management, until it is established how well IFG predict the subsequent development of T2DM and 
CVD. Is may be logical but is it certain that intervention that prevent the progression of IFG to T2DM (or 
IGT) also prevent the development of arterial hypertension and dyslipidaemia or CVD? 
In accordance with the DIGAMI II and the GAMI study [161,47], the DANSUK study have 
shown, that acute cardiac events are common also in fairly well glycaemic regulated patients. 
Encouragement to follow the current intensive ADA lifestyle and hypoglycaemic treatment regimes is 
therefore obvious. 
Although fairly well treated at referral, the majority of the patients in the DANSUK study 
were at higher risk for late diabetic and cardiovascular complications than the patients in the other 
randomized studies comparing intensive multifactorial threatment to usual care [105-111]. The DANSUK 
study is the first randomized controlled trial in the settings of comprehensive CR to obtain a mean HbA1c-
value below 6.5% in the intensively treated group (table 6.4). The patients with T2DM in the UC group 
also obtained a close to acceptable mean HbA1c-value below 7.0% after 12 months of follow-up, which is 
far better than control groups in other studies [105,170]. The DANSUK study have shown that intensive 
treatment of chronic hyperglycaemia in already fairly well treated patients with T2DM is possible and can 
be accomplished without severe side effects. 
An additional important aspect of the DANSUK study is the concept of adherence to 
therapy. Having suffered a cardiac event is a motivating factor itself to induce a lifestyle change. Being 
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offered comprehensive CR may further induce help to selfcare principals that the patients have to rely on 
and live by for the rest of their life. 
It was possible to develop and integrate a diabetes module in the programme of compre-
hensive CR by a team not specialized in endocrinology and diabetes care. It was feasible to obtain a 
significantly improvement of glycaemic and blood pressure control that in other studies have shown to be 
beneficial in reducing the risk of cardiac relaps. Comparing the outcome of the DANSUK study to other 
trials of CR rehabilitation, it is obvious that much is gained by focusing on glycaemic control also when 
comparing the lipid profiles, which is often improved when the hyperglycaemia is under control (table 
7.1). 
 
 
Table 7.1. Effect of comprehensive CR on clinical outcome in patients with T2DM    
               
   Main cardiac No. of Mean  Male Mean    % improvement/change     
  disease patients age % BMI HbA1c FPG TC HDL LDL TG METs BMI   
Hindman et al.56 IHD 292 63 73 32 NA -3.7 -3.6 -2.1 -4.8 -3.8 26.3 -0.02   
Milani et al.26 IHD 70 64 73 29 3.0 -6.0 -2.0 0 -3.0 -13.0 38.0 -1.0   
The DANSUK study IHD 32 62 70 31 -9.0 -11.0 -2.3 4.5 -8.7 0 3.5 -1.2   
Banzer et al.55 IHD 250 62 54 34 NA NA NA NA NA NA 26.0 0  
Bolded numbers denotes a significant change from baseline            
METs, metabolic equivalents (1 MET=3.5 ml O2/kg/minute); NA, not available; IHD, ischemic heart disease; BMI, body 
mass index; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride       
 
 
7.1. Study limitations and representativity 
Representativity of the DANSUK population 
As a randomized trial unbiased allocation of treatment was assured in the best possible way, but the 
nature of an open trial may have non-intended excluded those patients unwilling to consider adapting 
their lifestyle habits to the proposed intervention. Thus the following questions deserves some attention: 
• Does the DANSUK population represent a typical group of cardiac patients eligible for CR? 
• Are the two study groups altogether comparable? 
Predefined in- and exclusion criteria and a low participation rate (of 47%) could question the 
representativeness of the DANSUK population and the data collected on the excluded patients is not 
entirely sufficient to answer the first question. The excluded patients had a higher degree of co-
morbidities but the prevalence of known T2DM was similar in consenters as in non-consenters. Selection 
bias may affect the prevalence of IGM and risk factors and associations between these in both directions 
as illustrated in the following. Patients that were highly motivated for changing their lifestyle could have 
been more willing to consent. In the entire DANSUK population, 43% were overweight (BMI between 25-
30 kg/m2) and 33% were obese (BMI above 30 kg/m2). This may reflect an overrepresentation of obese 
patients and therefore an expected overestimation of IGM in the DANSUK study. Many patients of other 
ethnic origin, known to be prone for IGM, were excluded because of linguistic problems thereby possibly 
causing an underestimation of the true prevalence of IGM in this hospital population. Even though the 
program was highly individually tailored, the rather physical demanding exercise program could have 
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accomplished many older and physically more disabled patients not to consent. The non-consenters also 
had a higher degree of co-morbidities so the patients who finally consented to the DANSUK study may 
have been the healthiest. When adjusting for age, no difference in participation rate was found between 
men and women. 
 
Limitations of the study 
Limitations to the DANSUK study are divisible into general limitations related to study design and validity 
and to method specific limitations. As mentioned, randomization gives raise to an optimal comparability 
between study groups but it also bears the limitations of creating a highly selective population because of 
narrow in- and exclusion criteria. Baseline data was collected before randomization. The same kind of 
blinding was not possible in data collection during the study period. Knowledge of the glycaemic status in 
the patients at the time of referral to Bispebjerg University Hospital is partly incomplete. Although access 
to FPG during hospital admission and at the time of referral, the performance of an OGTT at the time of 
referral was not possible due to logistic difficulties. The OGTT was performed 3 months after 
randomization and after completion of the initial comprehensive rehabilitation programme that could have 
influenced the outcome although there was no statistically difference in metabolic subgroup assignment 
between the two study groups. Measurement of insulin resistance in patients with T2DM on the basis of 
the homeostasis model is not satisfactory but insulin clamp studies were never an opportunity. Finally the 
DANSUK study did not elaborate standardized questionnaires in collecting data on hypoglycaemic events 
that could have caused an underestimation of light and moderate experiences. 
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Part V: Implications from the DANSUK study 
8. Future prospects in CR of patients with IGM 
With IGM being more common among cardiac patients than NGT it is an absolute necessity for 
cardiologists to break down professional barriers and for endocrinologists to do the same facing a 
threatening future epidemic of T2DM and obesity. Units of CR should only serve as the ‘last line of 
defence’ in the effort to oppose this development. Efforts should be put in solving the questions in best 
performance of optimal cardiovascular risk stratification for myocardial ischemia in newly diagnosed 
T2DM. But fortunately the intensity of the glycemic control has increased during the last decade as seen 
in the difference in the baseline HbA1c in the DIGAMI studies [156,161]. 
Questions as to what kind of specialists and critical core of knowledge is needed to 
manage intensified treatment of patients with IGM in future CR programmes are discussable? Given the 
complexity of T2DM management the ADA recommends that patients with T2DM should receive medical 
care from a physician-coordinated team [301]. The DANSUK study has shown that integrating a diabetes 
module into an ongoing trial of comprehensive CR is feasible. The patients with T2DM or IGT obtained a 
higher degree of improved outcome compared to the patients with NGT. As in many single risk factor 
trials, the patients having the highest risk of disease often obtains the greatest benefit from treatment. 
The DANSUK study was no exception. In patients with T2DM or IGT and CVD, the CR programme should 
focus on a very aggressive risk factor control and enhancement of exercise capacity. Screening the 
referred patients for IGM seems inevitable and the OGTT is a vital necessity in doing so. The diabetes 
care in the DANSUK study was performed by physicians and nurses not specialized in diabetology and 
anyway all the type 2 patients underwent surveillance for retinopathy, nephropathy and foot ulcers as 
prescribed. If it is not possible to affiliate diabetologists to the settings of CR, the education of future 
cardiologists should contain at least some minimal educational skills in handling these patients. 
Diabetologists should also, as part of their specialization, obtain knowledge in suspecting myocardial 
ischemia, cardiac neuropathy, and in the treatment of other cardiovascular risk factors. Diagnosing T2DM 
in the unit of CR does not necessary oblige for a referral to a specialist. But because of the patient also 
being cardiac diseased certain clinical examinations and precautions as well as adjustments may have to 
be taken especially before exercising (figure 8.1). 
In contrary to the treatment of hypertension and dyslipidaemia, the treatment of hyper-
glycaemia is often a more challenging assignment for the caretaker. Because of the progressive nature of 
diabetes and the frequent variability of outcome measurements, it demands a more intense and 
continued intervention strategi and survaillance. Special considerations have to be taken in these patients 
because they may have more difficulties in losing weight than their metabolic normal counterpart 
because of metabolic differences, fear of hypoglycaemia, hypoglycaemic agents, limited physical activity, 
depressions and diet fatigue. 
The STENO 2 study concluded that there was a limited impact of lifestyle education in 
patients with T2DM [104]. There are several differences between the DANSUK study and the STENO 2 
study. Besides being a healthier and more homogeneous population the educational programme in the 
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intensively treated group was quite different in the STENO 2 study. The physical exercise was not 
supervised by a physiotherapist and the number of patients (incl. spouses) in the group sessions were 
relatively large compared to the DANSUK study.  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
Figure 8.1. - Initial examination and treatment of ST2DM in patients referred to CR 
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8.1. Barriers for implementation and success 
The reactions of the patients, when told that they suffer from a chronic disease, were very diversified. In 
some of the patients in the DANSUK study who had just survived an AMI, also being diagnosed with 
T2DM could be overwhelming. In other patients the diagnosis was almost neclectable compared to their 
cardiac disease. This was especially pronounced in patients with no symptoms of hyperglycaemia which 
was the majority of the patients. The patient education had to be highly adjusted to this diversity in 
pattern of reaction to information and this was a great challenge for the caretakers and the outcome 
depended of course of the characteristics of providers and provider-patient relationships. This emphasise 
the great challenge in chronic disease management. In the DANSUK study, 30% of the patients were 
stratified as HR patients. In consenting to the DANSUK study and being diagnosed with T2DM, many 
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types of intervention were offered and it had to be done with great caution and often over a long period. 
Many of these patients thought themselves to be relatively healthy and many frontiers had to be crossed 
from feeling healthy to become a candidate of 4-5 tablets a day. Very few of the patients with ST2DM 
had experienced symptoms directly related to hyperglycaemia such as polyuria, tactile disturbances, 
blurred vision etc. If the symptoms were present they were often neglected by the patients and 
considered of minor important compared to the symptoms of their cardiac disease. This was also a great 
challenge to the caretaker. It required great motivation to induce lifestyle changes and at the same time 
slowly persuade and implement 1 or 2 tablets.   
 
8.2. Concluding remarks 
The DANSUK study clearly demonstrates that the prevalence of IGM is high among patients referred to 
CR and that the classification disagreement between the WHO definition and the ADA criteria is 
considerable also in this kind of population. Without interfering with the overall comprehensive CR 
programme it was feasible to integrate a diabetes module, consolidate a need for focus on glucose 
intolerance and to create improved outcome in metabolic and blood pressure control that was superior to 
usual care. From the design of the DANSUK study, it is not possible to draw any conclusions to which of 
the treatment components were the most effective in producing the improvements that in other studies 
have been proven to reduce complications. But it would be headlong to conclude, that a difference in 
pharmacological treatment explain it all. The obtained improvements in all the metabolic groups rando-
mized to CR may still justify the concept of nutritional guidance, a school kitchen, the supervised physical 
exercise training and the other core components used in the DANSUK study. 
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Summary 
The prevalence of glucose intolerance is common among patients with acute myocardial infarction. The 
European Heart Survey recently revealed that having suffered an ischemic event it is more common to be 
glucose intolerant than having normal glucose tolerance. Whether the prevalence of impaired glucose 
metabolism in patients referred to cardiac rehabilitation is of the same magnitude is unclear as is the 
effect of comprehensive cardiac rehabilitation in patients with type 2 diabetes. 
First part of the dissertation reviews randomized controlled trials in diabetes prevention, 
treatment of hyperglycaemia, arterial hypertension, dyslipidemia and multifactorial intenvention. 
Second part describes the DANSUK study developed as a substudy to the larger 
DANREHAB trial that randomized 770 patients over a 3-year period to compare comprehensive cardiac 
rehabilitation to usual care.  As part also of the DANSUK study the last 201 included patients were also 
metabolic classified (DANSUK 1) and the intensively treatment of patients with type 2 diabetes or 
impaired glucose tolerance in the cardiac rehabilitation was compared to usual care (DANSUK 2). 
Third part concerns the results of DANSUK 1 where 42 patients (21%) had known type 2 
diabetes and the remaining 159 patients were metabolic classified according to the outcome of an oral 
glucose tolerance test (OGTT) and fasting plasma glucose values. Twenty-six patients (13%) had screen-
detected type 2 diabetes, 18% had impaired glucose tolerance, 9% isolated impaired fasting glucose and 
the remaining 39% had normal glucose tolerance. If an oral glucose tolerance test is omitted 18% of the 
patients with impaired glucose metabolism in the OGTT-cohorte are overlooked including 19% of the 
patients with screen-detected type 2 diabetes. Classification according to the American Diabetes 
Association criteria in the attempt to spare the oral glucose tolerance test increased the population with 
impaired glucose metabolism to 68% with only a minor improvement in classifying impaired glucose 
tolerance as impaired fasting glucose. The performance of an oral glucose tolerance test was essential in 
correctly classifying the patients in the DANSUK study. 
The fourth part describes the results of the intensified treatment compared to usual care 
where the patients with type 2 diabetes or impaired glucose tolerance in the cardiac rehabilitation group 
obtained a significantly greater reduction in mean HbA1c, blood pressure as well as an improvement of 
exercise capacity and insulin resistance after 12 months of follow-up. The patients with type 2 diabetes 
obtained a mean decline of HbA1c at 0.64% without weight increase and a mean decline in blood 
pressure at 8.4/4.9 mmHg. Both improvements were significantly different from the changes obtained in 
the usual care group. Until now the DANSUK study is the only study in the settings of comprehensive 
cardiac rehabilitation to obtain a mean HbA1c below 6.5% in the intensively treated group. As the 
prevalence of T2DM is increasing in Denmark, future comprehensive CR programmes must adopt a 
holistic approach to chronic disease management. 
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Resumé 
Forekomsten af glukose intolerance er høj blandt patienter med hjerteinfarkt. En større europæisk 
prævalensundersøgelse har nyligt dokumenteret, at glukose intolerance blandt infarktpatienter er mere 
almindeligt end normal glukose tolerance. Hyppigheden af glukose intolerance blandt patienter henvist til 
hjerterehabilitering er dårligt belyst i litteraturen ligesom der er begrænset viden om effekten af intensiv 
hjerterehabilitering hos patienter med type 2 diabetes endsige nedsat glukose tolerance. 
Første del af afhandlingen beskriver udfaldet af forskellige diabetesforbyggende 
randomiserede studier og giver en summarisk beskrivelse af studier over forekomsten af glukose 
intolerance blandt patienter med hjerteinfarkt. Den videnskabelige dokumentation for intensiv behandling 
af dyslipidæmi og arteriel hypertension hos patienter med type 2 diabetes gennemgås. Oversigten 
redegører desuden for evidensen for at  aggressiv hypoglykæmisk behandling har betydning for forløbet 
af makrovaskulær sygdom. 
Anden del af afhandlingen beskriver DANSUK studiet. Undersøgelsen var designet som et 
substudium til det store hjerterehabiliteringsprojekt DANREHAB på Bispebjergs Universitets Hospital, hvor 
770 patienter med iskæmisk hjertesygdom eller risiko herfor over en treårig periode blev inkluderet og 
randomiseret til henholdsvis intensiv hjerterehabilitering eller til sædvanlig efterbehandling 
(kontrolgruppen). De sidste 201 randomiserede patienter indgik i DANSUK studiet, der havde til formål at 
belyse 1)  Graden af glukose intolerance blandt hjertepatienter og patienter i risiko for hjertesygdom som 
var egnet til hjerterehabilitering (DANSUK 1) og 2) at vurdere effekten af en intensiveret 
hjerterehabilitering af patienter med type 2 diabetes eller nedsat glukose tolerance sammenlignet med 
sædvanlige efterbehandling. Opfølgning af kontrolgruppen foregik efter vanlige retningslinier i 
speciallæge ambulatorium eller i almen praksis  (DANSUK 2). 
Tredje del af afhandlingen beskriver prævalensdelen af DANSUK studiet, hvor alle 
patienter uden kendt type 2 diabetes blev inviteret til en oral glukose belastningstest 3 måneder efter 
inklusionen. To og fyrre patienter (21%) havde kendt type 2 diabetes og de resterende 159 patienter 
blev på basis af en oral glukose belastningstest (OGTT) og faste plasma glukose-værdier inddelt i 
yderligere 4 metaboliske grupper efter WHOs definition som nydiagnosticeret type 2 diabetes, nedsat 
glukose tolerance, isoleret faste hyperglykæmi eller normal glukose tolerance. Seks og tyve (13%) havde 
nydiagnosticeret type 2 diabetes, 36 patienter (18%) havde nedsat glukose tolerance, 19 patienter (9%) 
havde isoleret faste hyperglykæmi og 78 patienter (39%) havde normal glukose tolerance. Hvis man helt 
undlod at udføre en oral glukose belastningstest, ville 18% af patienterne i OGTT-kohorten med glukose 
intolerance efter WHO definitionen overses eller misklassificeres heriblandt 19% af patienterne med 
nydiagnosticeret type 2 diabetes. Patienterne blev reklassificeret i henhold til ADA kriterierne. Disse 
kriterier er nyligt anvendt for at simplificere diagnosticeringen af patienter med nedsat glukose tolerance 
med minimal brug af oral glukosebelastning. Anvendelsen af denne klassifikation af patienterne medførte 
en forøgelse af popula-tionen af glukose intolerante til 68% med en kun beskeden forbedret klassificering 
af nedsat glukose tolerante som havende faste hyperglykæmi. En helt ny gruppe patienter med isoleret 
faste hyperglykæmi, som efter WHO definitionen tidligere havde haft normal glukose tolerance, blev 
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introduceret. For korrekt diagnostik af type 2 diabetes og nedsat glukose tolerance i DANSUK 
populationen krævedes således udførelsen af en oral glukose belastningstest. 
Fjerde del af afhandlingen beskriver interventionsdelen af DANSUK studiet. Patienter 
randomiseret til intensiv hjerterehabilitering med type 2 diabetes eller nedsat glukose tolerans blev over 
12 måneder tilbudt intensiv hjerterehabilitering med et integreret diabetes modul. Diabetesmodulet 
bestod af såvel gruppeundervisning som individuel opfølgning sideløbende med det etablerede intensive 
rehabiliteringsprogram. Efter 12 måneder havde patienterne med glukose intolerance opnået en 
signifikant bedre glykæmisk og blodtryksmæssig kontrol ligesom de havde forbedret deres fysiske 
kapacitet og mindsket deres insulinresistens i højere grad end de glukose intolerante patienter, der havde 
modtaget sædvanlig efterbehandling. Patienterne med type 2 diabetes randomiseret til hjertereha-
biliteringsenheden havde et gennemsnitligt fald i det systoliske og diastoliske blodtryk på henholdsvis 8.4 
mmHg og 4.9 mmHg, hvilket var signifikant større end kontrolgruppen (p<0.05). Det gennemsnitlige fald 
i HbA1c var 0.65% hvilket ligeledes var signifikant forskelligt fra den sædvanlige efterbehandling 
(p<0.05) og 66% af patienter med type 2 diabetes i den intensivt behandlede gruppe opnåede en HbA1c 
på mindre end 6.5% efter 1 år. Resultaterne fra DANSUK studiet giver overvejelser omkring nødvendig-
heden af at implementere og integrere et diabetes modul i fremtidens hjerterehabiliteringskoncept. 
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